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General Introduction
General Introduction
1. Neural Tube Defects
Neural tube defects (NTDs) including anencephaly and spina bifida are 
among the most common human birth defects, and involve defective 
formation of the brain and/or spinal cord (Fig. 1). The defects result from a 
failure to complete neural tube closure during early embryonic development, 
a process that takes place in humans in the fourth week of gestation. NTDs 
occur with an incidence varying from 1 in 3000 births in Finland to 1 in 300 
births in UK and Ireland (1). In the Netherlands the incidence is 
approximately 1 in 700 births (2). Epidemiological data show that most 
NTDs occur as a consequence of a complex interaction between 
environmental and a variety of predisposing genetic factors, which is 
indicative for a multifactorial process (3). The observed effects of folic acid 
and/or myo-inositol suppletion on neural tube closure, combined with risk 
factors such as paternal exposure to chemicals and radiation, suggest an 
important role for the environment. This suggestion is confirmed by the 
observed inverse correlation between the incidence of NTDs and 
socioeconomic status (4). On the other hand, the occurrence of familial NTDs 
and the increased risk observed for children of affected parents suggest the 
existence of predisposing genetic factors (5, 6). The heritability in human 
NTDs, which can be defined as the relative contribution of genetic factors, 
has been estimated to be approximately 60 percents (3).
A useful model to explain such multifactorial inheritance is the so-called 
liability/threshold model. According to this model discontinuous phenotypes 
can be explained by assuming that the sum of adverse genetic and/or 
environmental factors must exceed a certain threshold before an abnormal 
phenotype such as NTDs becomes manifest (7). In the case of spina bifida, a 
severe form with open lesions exists (spina bifida aperta) and a less severe
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form in which the lesion is covered with skin (spina bifida occulta). 
Particularly this latter form is not always recognized and in fact it is has been 
suggested that latent lesions exist in at least 15% of the total adult human 
population (8, 9). In theory persons with a mild occult spina bifida lesion 
might be predisposed to more severe NTDs, of which the manifestation 
depends on several other adverse genetic and/or environmental factors. Some 
controversy regarding this classification exists and it has been stated that in 
mice spina bifida occulta is usually genetically and developmentally 
unrelated to exencephaly (a mouse analogue for human anencephaly) or 
spina bifida aperta (10), but from a developmental point of view one could 
state that the defects seen in spina bifida occulta are also prerequisite for the 
aperta phenotype.
Figure 1. Spina bifida aperta: A common human 
neural tube defect. Clearly visible is the open 
lesion with neural spinal cord tissue exposed. 
This kind o f defect causes the loss o f control 
over the lower body parts leading to 
incontinence and wheelchair dependence.
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2. Neural Tube Development
2.1 Introduction
After the formation of the ectoderm, mesoderm and endoderm layers (Fig. 
2A) by a complex process called gastrulation, neural tube development or 
neurulation can take place. Formation of the neural plate is the first 
prerequisite for this process to occur. Neural differentiation is the default 
pathway of the ectoderm, but is switched to an epidermal fate by the growth 
factor Bmp-4, which is initially expressed throughout the entire embryo. The 
transient embryonic structure called the notochord (Fig. 2A) secretes sonic 
hedgehog, a morphogen that induces inhibitors of Bmp-4 function and 
expression (e.g. noggin and Wnt respectively). These inhibitors allow 
ectodermic cells to follow their default neural fate and thus form the neural 
plate (11). In figure 2 the subsequent steps in (Xenopus) neurulation are 
depicted. Upon formation of a neural plate (A, B), a complex of 
morphogenetic processes gives rise to a neural groove (B). At close 
proximity of the tips the groove is closed by overgrowth of the epithelial 
cells (C), much like in wound healing, which eventually allows the formation 
of the neural tube (D, E). During the process of neurulation, complex 
interactions within the neural tissue and between neural cells and surrounding 
tissue, induce cellular responses such as proliferation, apoptosis, 
differentiation and migration, that are all necessary for normal neural tube 
development (12).
2.2 Mouse NTDs models
Several studies on mouse models with NTDs have provided evidence for the 
involvement of specific genes which function during embryonic neural tube 
development. The genes found to be involved in the various NTDs models
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are widely heterogeneous in function, and often the NTD mutations show 
variable, low penetrance or sometimes complex inheritance patterns (e.g. 
SELH/Bc, Abl/Arg, Mena/Pro filin1). Even though various models with 
human-like multifactorial genetic causes exist in which the NTD risk can be 
reduced by different maternal nutrient supplements, including folic acid 
(Pax3, Cart1, Cd mutants), inositol (ct) and methionine (Axd), only few 
NTD factors in mice can directly be associated with human NTDs.
Figure 2. Subsequent steps in neurulation o f a developing Xenopus embryo as seen 
in cross sections (12). When after gastrulation the ectoderm, mesoderm and 
endoderm layers have been formed (A), the neural plate is induced which curves 
into the neural groove (B). The epithelial cells at the elevated tips o f the groove fuse 
(C, D), allowing formation o f the neural tube (E). At the site o f neural closure neural 
crest cells (nc) are formed which express Pdgfra and are involved in formation of 
numerous other tissues varying from skull to melanocytes in the skin (E).
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There are now more than 60 known mouse mutants and strains with NTDs 
(Table 1). In most of these mouse models, the NTDs are exencephaly or 
spina bifida or both. In addition the mutations in most mice models generally 
cause syndromic effects, while in humans NTDs are usually not associated 
with other malformations or defects (16). Most of the single gene mutations 
that cause neural tube defects (NTDs) in mice also cause severe embryonic 
lethal syndromes, in which exencephaly could be a non-specific side effect. 
Only a few mutants exist (e.g., Trp53, Macs, Mlp or Sp), in which other 
defects besides NTDs may be present, but affected foetuses at least can 
survive to birth (10, 13). These observations seem to limit the usefulness of 
mouse models for understanding genetic factors involved in humans NTDs. 
One should realize, however, that in humans only 20-25% of all conceptions 
lead to full term pregnancy. Early embryonic death (75-80%) caused by 
NTDs is usually not detected and generally only viable patients are included 
in the analysis. In these viable patients one might probably expect more 
subtle genetic alterations instead of the complete disruption of genes that are 
involved in neural tube formation in mouse models. In addition most parents 
of NTDs patients are unaffected, emphasizing the importance of models with 
genetic defects that show variable penetrance.
Line name PHENOTYPE
Abl/arg Developmental delay, variable exencephaly, abnormal 
neuroepthelium
Ad3h (Ps1) Fused column
Ap2 Exencephaly
Apo B Hydrocephalus, variable closure defects
Arnt Variable exencephaly
Axd (axial defects) Spina bifida
Blm Developmental delay in closure
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Bmp-2 Open neural tube
Bn(bent tail)(zic1) Variable exencephaly and spina bifida
BRCA1 Variable exencephaly, anencephaly and or spina bifida
Cart1 Variable exencephaly
CBP NTDs, open neural tube
Cd (crooked tail) Exencephaly
c-myc Variable NTDs
Csk Exencephaly
Ct (curly tail) Exencephaly and/or spina bifida; due to growth misbalance.
Cyp26A1 Variable spina bifida
Dlx5 Variable exencephaly
E2f5 Hydrocephalus
F52 Not lethal, Variable exencephaly and/or spina bifida
FGFR1 Spina bifida
FN Kinked neural tube
Folbp1 Folic acid rescued open tube
Gadd45A Exencephaly
Gata3 Variable exencephaly
Gata4 Exencephaly
Hand1 Crooked neural tube
Hdh Variable exencephaly
Hes1 Exencephaly
Hic1 Variable exencephaly
Hif1a Mesenchyme apoptosis induced open neural tube
HNF-3 beta Abnormal neural tube
Hox1.6 Delayed cervical closure, perinatal lethal
Hspg2 Variable exencephaly, bone deformations
Hus1 Exencephaly variable kinked neural tube
Int-2(Fgf3) Abnormal vertebrae, not lethal
Jmj Variable exencephaly
K14-shh Variable spina bifida
Kif3a Hydrocephalus
Laminin alpha 5 Variable exencephaly
Macs Omphalocele, anencephaly
Mena/profilin Exencephaly
Mesp2 Defective neural arch development, spina bifida, perinatal 
lethal
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Mfh1 Vertebral defects
Mhox (Prx1) Vertebral defects, spina bifida
Mlp Exencephaly
NCAM Exencephaly
Nf1 (Fcr) Variable exencephaly
n-myc Thin neuroepithelium
Otx2 Variable abnormal neural tube
P300 Open neural tube
Patch (Pdgfra) Vertebral defects, absent dorsal roof of neural tube, spina bifida
Pax3 (Splotch) Exencephaly and/or spina bifida
Pdgfra Vertebral defects, absent dorsal roof of neural tube, spina bifida
Ptch (ptc) Open neural tube
Raldh2 Exencephaly
Rfng Variable exencephaly
SELH/Bc Exencephaly
Shh Absent vertebral column
Shrm Exencephaly
Sil Variable exencephaly and spina bifida
Ski Delayed closure, variable exencephaly
Smad5 Exencephaly
TbetaR1 Kinked, thin neural tube
Terc Variable exencephaly, spina bifida
Tgfb2 Spina bifida occulta, perinatal lethal
Tr53 (p53) Variable exencephaly
Traf6 Variable exencephaly
Tsc2 Delayed closure, variable exencephaly
Twist Exencephaly
Vcl Exencephaly
Wnt3a Ectopic neural tube
Xrcc2 Variable exencephaly and spina bifida
Table 1. Overview o f mouse lines that display various forms o f neural tube defects, 
with indicated phenotype.
2.3 Neural fold elevation
One hypothesis for the origin of NTDs in mice states that it is caused by 
failure of the process called neural fold elevation. This process involves the
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elevation of the tissue that has to fuse to close the neural tube. In mice neural 
tube closure is initiated at four different sites, giving rise to four well-defined 
mechanistically distinct closure zones, as depicted in figure 3. Failure of 
elevation leads to: split face (closure 3), exencephaly (closure 2), rachischisis 
(all parts of closure 1), or spina bifida (caudal closure 1). The genes mutated 
in several mouse NTD models (see table 1) that involve actin regulation 
(Abl/Arg, Macs, Mena/Profilin1, Mlp, Shrm, Vcl), support actin-mediated 
cellular movements as the main factor for neural fold elevation. On the other 
hand NTD mutants with genes involved that have a basic mitotic function 
(Gadd45a, Terc, Trp53) suggest that failure of neural fold elevation reflects 
aberrant growth of the underlying tissue. As is shown in figure 2 most tissue 
growth is seen in the mesodermal compartment, flanking the notochord and 
the developing neural tube. It seems as if the neural groove is formed 
because the neural tissue is pulled down by the notochord, which is attached 
to the endoderm. Therefore the process of elevation might at least partially 
also depend on mesodermal growth. Besides proliferation other mechanisms 
that influence tissue growth are faulty regulation of apoptosis (Trp53 or 
p300), premature differentiation (Hes1) or abnormal telomerase complex 
(Terc) (10, 13).
2.4 Polymorphisms and NTDs
As opposed to mutations, polymorphisms are non-pathogenic variances in 
DNA sequence involving single nucleotides (e.g. SNPs) or multiple 
nucleotides (e.g. insertions or deletions). Polymorphisms, as might be 
expected, are mainly found in non-protein encoding DNA. Polymorphisms 
that are situated in parts of the genome that contain sites important for 
correct spatio-temporal expression of developmental genes, could give rise 
to the more subtle changes that are necessary for individual development. It
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is therefore very well feasible that many genetically determined individual 
qualities are caused by differences in expression patterns due to polymorphic 
expression regulating sequences.
In spite of their non-pathogenic nature, specific polymorphisms can 
determine susceptibility to congenital defects. An interesting example exits 
of (yet undefined) genetic polymorphisms that play an important role in 
determining susceptibility to NTDs in Splotch mutant mice. In mice the site 
at which cranial neural tube closure starts (closure 2) is different between 
inbred mice lines. This provided a tool to investigate the influence on NTDs 
genesis of this apparent genetically determined variance in neural tube 
closure. Strains with a caudal location of closure 2 (caudal) were compared 
to strains with a rostrally positioned closure 2 (rostral). By back-crossing the 
Splotch (Sp/Pax3) mutant gene onto the caudal background, using Sp 
transferred onto the rostral background as a control, it was found that the 
frequency of cranial NTDs was significantly reduced in Sp homozygotes 
after transfer to the caudal background, confirming a protective effect of 
caudal closure 2. In contrast, Sp homozygotes on the rostral background had 
a persistently high frequency of cranial NTDs of approximately 80%. The 
frequency of spina bifida was not altered in either backcross, emphasizing 
the specificity of this genetic effect for cranial neurulation (14).
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Figure 3. Neural tube closure in the human embryo initiates simultaneously at 3 sites 
(1-3), o f which 1 and 2 initiate bi-directional closure (15). Between the closure 
initiated by 2 and 3 the rostral neuropore is situated. At the caudal end o f the closure 
zone initiated by 1, the caudal neuropore is situated, which closes two days after the 
rostral neuropore. After closure o f the neural tube (primary neurulation), further 
differentiation and canalisation o f neural tissue in the tail bud occurs (secondary 
neurulation). In mice an additional (4) unidirectional neural tube closure initiation 
site has been found.
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3. Axial Development, The Vertebral Column
As stated before the process of neural tube closure is not independent of the 
surrounding tissue and in NTDs also non-neural tissues are affected. In adult 
vertebrates the neural tissue is protected by surrounding bony structures such 
as the skull and the vertebral column, which are severely affected in 
anencephaly and spina bifida respectively. Actually many mouse models 
with variable penetrance of the NTDs phenotype, such as “bent tail” and 
“curly tail” or “rib fusions”, are recognized by and even named after the 
minor defects of the axial skeleton seen in the mice without NTDs. Therefore 
the actual location of the defect that causes failure of neural tube closure is a 
matter of discussion; many arguments exist in favour of a neural location as 
well as in favour of a location in the surrounding mesodermal tissue.
3.1 The somites
Just after neurulation the vertebral column starts to develop from somites 
(figure 4), the segmental units of the paraxial mesoderm (17). The 
boundaries of the definitive vertebrae are shifted by half a segment as 
compared to those of the somites. This so-called resegmentation can be 
observed in various species. By applying the quail-chick grafting technique, 
it has been shown that each vertebra is made up of cells from two adjacent 
somites (18). Later studies came to similar results showing that specific 
somite parts contribute to different skeletal structures; for instance the 
mesenchymal core of the somite (somitocoel cells) contributes to the 
intervertebral discs. In this way, different compartments of the somites have 
been identified that differentiate into the sclerotomes, which form the various 
structures of the definitive skeleton (19-22).
12
Chapter 1
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tp ---- sp neural tube BMP-4
p d g f r a /pa :
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glia —  
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sclerotome
Figure 4. Developing vertebra (4A) surrounds the neural tube as the sclerotome (4B) 
forms the vertebral body (vb) around the notochord while different compartments 
form the pedicles (p) with its transverse processes (tp), the neural arches, the 
spinous process (sp) and the ribs (r). Many essential genes are involved in this 
process including PAX1 and PDGFRA, o f which the latter is also expressed in glial 
cells in the neural tube. BMP-4 and sonic hedgehog provide a dorsal and ventral 
signal, respectively, which are essential for specific ventral and dorsal structures to 
form (4b).
The development of the vertebral column from the somites does also not 
occur independently but requires signals from the surrounding structures. 
After removal of neural tube and notochord, for instance, the somites are not 
able to form the vertebral column. In such embryos, the body wall consists 
only of undifferentiated connective tissue. After removal of the notochord 
alone, vertebral bodies and intervertebral discs do not develop, but neural 
arches can be observed. After removal of only the neural tube, however, 
neural arches do not form (23).
3.2 Vertebrae formation
After sclerotome differentiation these bone precursor cells fill the ventral 
cell-free subcompartment in which subsequently the vertebral bodies and the 
intervertebral discs develop (Fig. 4). This peri-notochordal space contains
13
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initially only extracellular matrix material that connects the sclerotomal cells 
with the basement membrane of the notochord and functions as a substrate 
for the invading cells (23). The originally paired and migrating ventral 
sclerotomes fuse in the midline near the notochord and form the vertebral 
bodies and intervertebral discs, a process that requires sonic hedgehog 
signalling by the notochord which induces the expression of the earliest 
known sclerotomal marker Paxl in the flanking paraxial mesoderm. In these 
cells the transcription factor Pax1 and the platelet-derived growth factor a- 
receptor (Pdgfra) are then co-expressed. The most ventral parts of the neural 
arches fuse to the anterior parts of the vertebral bodies and form the pedicles. 
The dorsal sclerotomes of each side grow out and gradually surround the 
neural tube between the roof plate of the neural tube and the dermis, and fuse 
in the midline to form the most dorsal part of the neural arches and the 
spinous processes. This dorsal development depends on Bmp-4 signalling 
from the neural tube and coincides with continuous Pdgfra expression, but 
expression of Pax1 diminishes (23, 24). During spina bifida genesis neural 
arch development is severely disturbed. The NTDs and profound defects in 
the axial skeleton found in mice with defective Pdgfra expression will be 
discussed in the next sections.
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4. PDGFRA and Embryonic Development
4.1 The PDGFRA gene
The human PDGFRA gene is located on chromosome 4q12, spans 
approximately 65 kb of DNA and contains 23 exons (figure 5). The 5'- 
untranslated region of the mRNA is encoded by exon 1, while a large intron 
of 23 kb separates exon 2 encoding the translation initiator codon ATG and 
the signal sequence. The general structure of the PDGFRA gene is very 
similar to those of its family members, platelet-derived growth factor ß- 
receptor (PDGFRB), the steel factor receptor (c-KIT) and macrophage 
colony stimulating factor-1 receptor (c-FMS). These genes are similar with 
respect to the locations of exon/intron boundaries and the encoded protein 
parts: the extracellular immunoglobulin-like domains, the transmembrane 
domain, the split cytoplasmic tyrosine kinase domains, and the kinase 
insertion domain.
Figure 5. Genomic structure of the human P D G F R A  gene (Chr. 4q12). Depicted are 
the two promoters P1 and P2 (grey arrows), as well as the 23 exons and the TCCE 
(black boxes).
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Cells expressing PDGFRA show a characteristic 6.4-kb transcript, which 
contains all information for the full-length receptor, in combination with a 
3.0-kb alternatively terminated and spliced transcript. Two transcription start 
sites have been mapped to positions 393 and 174 bp upstream of the ATG 
translation initiator codon by S1 mapping and primer extension analysis on 
PDGFRA cDNA encoding the full-length receptor (25, 26). In cells that are 
negative for the 6.4-kb and 3.0-kb transcripts sometimes expression of two 
aberrant transcripts of the human PDGFRA gene of 5.0 kb and 1.5 kb can be 
detected (e.g. in undifferentiated human embryonal carcinoma cells, such as 
Tera-2 clone 13). Expression of the 1.5-kb transcript has been shown to be a 
prognostic marker for human testicular tumours (27-29). These transcripts 
disappear upon differentiation of these human embryonic cells and the 6.4­
kb transcript in combination the 3.0-kb transcript is then expressed instead. 
The alternatively spliced 3.0-kb and 1.5-kb transcripts contain a so-called 
“terato-carcinoma cryptic exon” or TCCE sequence after which alternative 
transcription termination occurs. The 5.0-kb and 1.5-kb transcripts contain in 
addition intron 12-derived sequences as a consequence of transcription 
initiation by a second promoter situated in intron 12. cDNA cloning 
combined with genomic analysis has shown that the 5.0, 3.0 and 1.5-kb 
PDGFRA transcripts potentially encode N- and C-terminally truncated 
proteins (Fig. 6), although actual protein products have not been identified 
sofar.
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Figure 6. Survey o f human P D G F R A  transcripts and putative protein products. 
(Left) Organization o f P D G F R A  transcripts, with corresponding sizes (kb). Black 
areas indicate regions corresponding to the full-length receptor sequence, grey areas 
indicate intron 12 sequences, and hatched areas TCCE sequences. Lines indicate the 
location o f the PCR primers used for individual detection o f these transcripts. 
(R ight) Putative protein products corresponding to the respective transcripts. Grey 
areas are derived from intron 12 and exon 12 sequences (alternative reading frame), 
and hatched areas are from TCCE. TM stands for transmembrane region, and TK-1 
and TK-2 for tyrosine kinase domains. Looped structures indicate immunoglobulin­
like domains (28).
4.2 PDGFRA function
Platelet-derived growth factor (PDGF) is a widely expressed growth factor 
that is thought to be involved in many biological processes, including 
embryonic development, wound healing, arteriosclerosis and neoplasia (28, 
30-33). Both the a-and ß-receptor belong to the family of tyrosine kinase 
receptors. The PDGF receptors dimerize upon ligand binding, which results 
in kinase activation and receptor transphosphorylation on specific tyrosine 
residues. This phosphorylation event initiates a cascade of signalling events, 
finally resulting in a biological response (38). PDGF can occur as dimers of 
4 different gene products (A-D), of which 5 isoforms are known; AA, AB 
and BB, and the protease-activated ligands, CC and DD (34-37). These
17
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ligands bind with different affinity to the PDGF a -  and ß-receptor. PDGF- 
BB and PDGF-DD are the high affinity ligands for PDGFRB. PDGFRA can 
be activated by all ligands, although PDGF-DD can only activate PDGFRA 
when it is dimerized with PDGFRB. Differences in contribution of either 
receptor subtype to the different biological responses of PDGF seem 
predominantly caused by differences in expression patterns, since receptor 
signalling via SH2-domain containing messengers is highly conserved 
between PDGFRA and PDGFRB. In transgenic mice, however, interchanged 
intracellular domains do give rise to cardiovascular problems when Pdgfrb is 
attached to a Pdgfra intracellular part (39).
4.3 PDGFRA expression
Accumulating evidence indicates an essential role for PDGFRA in early 
embryonic development. Although present in all cells of the pre-implantation 
embryo from the two-cell stage onwards (40) Pdgfra expression becomes 
limited to mesoderm- and certain neural crest-derived structures after 
implantation (24, 41-44). Expression of Pdgfra, and thus responsiveness to 
all Pdgf isoforms, remains then strictly regulated during embryonic 
development. Both Pdgfa and Pdgfra mRNA is expressed prior to and more 
abundantly than Pdgfb and Pdgfrb mRNA during early mouse post­
implantation development (45). As might be expected from what is known 
about the human PDGFRA transcripts, the results of Pdgfra expression 
studies during mouse embryo genesis using whole-mount full length receptor 
immunostaining tend to differ somewhat compared to those of in situ RNA 
hybridisation studies (24, 40). Expression patterns according to 
immunohistochemical studies using a monoclonal anti-Pdgfra antibody on 
tissue sections were not in line with an exclusive staining of only the 
paraxial mesoderm, whereas other investigators concluded that most if not
18
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all mesodermal cells express Pdgfra. Moreover, no Pdgfra protein was 
detected in embryonic erythrocytes, which have previously been suggested 
to express Pdgfra. On the basis of Pdgfra protein detection, the overall 
expression patterns found were as follows: During the pregastrulation stage, 
Pdgfra is expressed only in primitive endoderm, particularly in the 
ectoplacental cone, the future placenta. Upon gastrulation, it is expressed at 
high levels in the paraxial mesoderm. This expression continues after its 
differentiation into somites. Along with the differentiation and migration of 
the sclerotome, Pdgfra expressing cells begin to become distributed 
throughout the embryonic mesenchyme. During organogenesis, particularly 
intense expression has been detected in regions of epithelial and 
mesenchymal interaction, such as the tooth bud and bronchi. In addition to 
mesodermal derivatives, the developing lens, apical ectodermal ridge, glial 
precursor cells, neural crest, cardiac valves, and choroid plexus express 
Pdgfra. Results from both whole-mount immunostaining and in situ 
hybridisation show that Pdgfra is abundantly expressed, which underlines the 
importance of its function during embryogenesis. Although the impact of 
Pdgfra expression during later development seems to decline, expression of 
the Pdgfra gene still correlates with the later developing tissues. The most 
extensively studied example is glia cell specific Pdgfra expression in the 
developing central nervous system (46-48). Pdgfa knock out mice show a 
severe hypomyelinisation while humans tumours arising from glial cells 
display a specific pattern of PDGFRA expression (49, 50, 51 ) or contain 
PDGFRA gene mutations (52, 53).
4.4 Role o f PDGFRA in NTDs
Additional information concerning the importance of PDGFRA expression 
during early embryonic development comes from studies on transgenic mice,
19
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which carry mutations in the Pdgfra gene. Mice with a targeted null mutation 
in the Pdgfra gene and also so-called Patch mutant mice with a natural 
deletion of the chromosomal region that includes the total Pdgfra gene both 
show severe spina bifida combined with embryonic lethality in their 
homozygous form (54, 55). The multiple abnormalities in the vertebral 
column, the neural tube and other tissues of the targeted Pdgfra null mutant 
embryo were comparable to those that were found in the homozygous Patch 
mutants. Cervical vertebrae showed extensive structural alterations and 
anterior-posterior fusions of the arches, while the vertebral bodies were 
abnormal and bilaterally asymmetric. In thoracic vertebrae, and to lesser 
extent cervical vertebrae, the neural arches failed to form the normal convex 
structure observed in wild-type embryos and were spread out. In 
combination with an abnormal neural tube this resulted in spina bifida (Fig. 
7) and in an abnormal curvature of the spinal column. The neural tube was 
dilated and abnormally thin at the dorsal site and lacked a roof plate, which 
might be correlated with an abnormal function of the cerebral fluid 
producing choroid plexus. However, although slightly delayed in 
development, sacral and caudal vertebrae appeared normal. In addition 
several other defects were observed including cleft face, fused ribs, severe 
bleeding, impaired lung growth and incidentally omfalocele (54, 55).
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Figure 7. A comparison between vertebrae (right part) and cross-sections (left part) 
o f wild type and P d g fra  mutant mice (P dg fra  -/-) revealed multiple defects, 
including incomplete neural tube (left part, arrows) and malformed neural arches 
(right part).
(Adapted from 54, 55)
In Pdgfra negative Xenopus embryos similar defects were observed, whereas 
the first defects were already visible at the gastrulation stage (56). Together 
with our unpublished observations of normally developing rat embryos that 
were treated at the 1-5 somite stage with AG1295, a PDGF receptor-specific 
tyrosine kinase inhibitor, these experimental findings suggest that the defects 
seen in null mutants primarily arise from defective early mesoderm 
development.
Yeast artificial chromosome (YAC) transgene expression after pronuclear 
injection of a 380 kb YAC containing the human PDGFRA gene was found 
to rescue the profound craniofacial abnormalities and spina bifida observed 
in Pdgfra targeted null mice resulting in prolonged survival until birth. 
However, the pups still died from respiratory failure due to a defect in lung
21
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growth, stemming from failure of the transgene to be expressed correctly in 
lung smooth muscle progenitors (57). The finding that transcriptional 
upregulation of Pdgfa, Pdgfra and Pdgfrb expression by all trans-retinoic 
acid enhances alveolarization in neonates and reinitiates alveolarization in 
emphysematous adult rat lungs, confirms the importance of Pdgfra 
expression in lungs (58).
4.5 Interaction o f two adverse factors in a digenic mouse model 
Like many other mouse NTD models those lacking a functional Pdgfra 
exhibit early embryonic lethality. This suggests that similar kinds of 
mutations are not involved in human neural tube defects such as spina bifida, 
since these are not lethal. The large number of genes found in mouse models 
to be involved in neural tube development, in combination with 
epidemiological data of human NTDs, suggests the possibility for NTDs to 
arise as a sum of multiple adverse factors. These adverse factors would lead 
to a developmental disturbance or delay that cannot be overcome during 
further development. Only few direct experimental examples exist that 
support such a theory. Well-defined non-lethal adverse factors, such as the 
Undulated (Un) mutation in Pax-1 and the Patch (Ph) chromosomal deletion 
which includes Pdgfra, are required to perform such experiments in mice. 
Undulated-Patch double-mutant mice (Un/Un, Ph/+) show congenital 
anomalies including non-lethal spina bifida, while the single-mutant mice 
(Un/Un) and the Patch heterozygotes (Ph/+) do not show the spina bifida 
phenotype. This shows that a phenotype can result from an interaction of two 
mutated loci, in this case Pax1 and Pdgfra. This example of digenic 
inheritance may explain the often sporadic nature of spina bifida in humans 
(59). Since Pdgfra-mutated mouse strains show no effect on Pax1 expression 
in the segmented paraxial mesoderm (54) it is very well feasible for Paxl to
22
Chapter 1
act as an upstream regulator of the Pdgfra. The loss of one Pdgfra allele in 
combination with a mutated upstream regulator might lead to defective 
Pdgfra transcription. Subsequent aberrant PDGF signalling could then lead 
to apoptosis, premature differentiation or a prolonged undifferentiated, 
proliferative status of embryonic tissue involved in axial development (60­
63), ultimately resulting in developmental defects such as NTDs. In addition 
a single PAX1 mutation has been identified in a patient with spina bifida 
(64), which again suggests the discussed mechanism to be involved in 
human NTDs.
5. Objectives of the present study
Genesis of the neural tube or neurulation is a major morphogenetic event 
during early embryonic development and disturbances of this process can be 
lethal or lead to severe birth defects including spina bifida. The discovery of 
the (partially) protective effect of maternal folic acid supplementation shows 
that even complex processes such as neural tube development can be 
controlled externally by rather simple proceedings. In order to ultimately 
prevent neural tube defects, identification and analysis of genes and 
developmental mechanisms involved in the neurulation process are 
indispensable. Understanding of mechanisms that predispose to congenital 
neural tube defects will be necessary for the development of additional 
prevention strategies.
Extrapolation of the mouse digene Undulated-Patch NTD model 
combined with the Pdgfra null mutant, suggests that deregulated PDGFRA 
expression may also play a role in human NTDs. This is also indicated by the 
observation of a single PAX1 mutation in a non-syndromic NTDs patient,
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and of a PAX3 mutation in a syndromic NTDs patient (64,65). Both PAX 
genes have been associated with Pdgfra function in mice. Here we 
hypothesise that deregulation of PDGFRA transcription is a central 
mechanism in human NTDs genesis. Accordingly the main objective of the 
present study is the identification of regulatory genes involved in 
transcriptional regulation of PDGFRA and their mechanism of action, and to 
test them as candidate genes involved in human NTDs.
Chapter 1 of this thesis serves as an introduction and a review on NTDs 
and the PDGFRA gene. Chapter 2 describes how PDGFRA transcription 
regulating sequences were cloned and analyzed in order to study upstream 
regulators. In chapter 3 we show an analysis of the PDGFRA promoter 
polymorphisms that exist in a group of spina bifida patients versus a control 
group. In chapter 4 the functional analysis of NTD-associated Paxl 
mutations with respect to DNA binding and transcriptional regulation of the 
PDGFRA gene is presented. Chapter 5 describes the early regulation of 
PDGFRA transcription during cell differentiation in human embryonal 
carcinoma cells by NTD-associated homeobox transcription factors. Our 
hypothesis that deregulation of PDGFRA-transcription is a main event in 
NTDs genesis in humans is finally discussed in chapter 6.
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Molecular cloning and functional 
characterization of the human platelet-derived 
growth factor a-receptor gene promoter
The data presented in this chapter were published in part in Oncogene 10 (1995) 
1667-1672, by: Gijs B. Afink, Monica Nistér, Bianca H.G.J. Stassen, Paul H.L.J. 
Joosten, Pascale J.H. Rademakers, Erik Bongcam-Rudloff, Everardus J.J. Van 
Zoelen & Sietse Mosselman
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Abstract
Expression of the platelet-derived growth factor a-receptor (PDGFRA) is 
strictly regulated during mammalian development and tumorigenesis. The 
molecular mechanisms involved in the specific regulation of PDGFRA 
expression are unknown, but transcriptional regulation of the PDGFRA gene 
is most likely to be involved. This study describes the molecular cloning of 
the non-coding exon 1 and approximately 2 kb of 5’ flanking region of the 
human PDGFRA gene. This 5’ flanking region is a functional promoter of 
the PDGFRA gene as concluded from its capacity to drive luciferase reporter 
gene expression in an orientation dependent manner. Analysis of 5’ promoter 
deletion mutants revealed that the region from -441 to + 118 is sufficient to 
establish high level promoter activity. In addition the morphogen retinoic 
acid, in combination with dibutyryl cAMP, gives a 22-fold induction of 
PDGFRA gene promoter activity in human embryonal carcinoma cells. This 
indicates that the cloned PDGFRA gene promoter contains the necessary 
elements to regulate PDGFRA expression in response to cell growth 
regulatory factors.
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Platelet-derived growth factor (PDGF) is a potent mitogen for mesenchymal 
and glial cells and is thought to play an important role in wound-healing, 
atherosclerosis, neoplasia and embryogenesis (1-4). PDGF can occur as three 
isoforms, AA, AB and BB, which bind with different affinities to the PDGF 
a -  and ß-receptor. PDGF BB is the only high affinity ligand for the platelet- 
derived growth factor ß-receptor (PDGFRB), but the platelet-derived growth 
factor a-receptor (PDGFRA) can bind all three isoforms (see general 
introduction for an update). Both the a -  and ß-receptor belong to the family 
of tyrosine kinase receptors. Upon ligand binding PDGF receptors dimerize, 
which results in kinase activation and receptor transphosphorylation on 
specific tyrosine residues. The phosphorylated receptors subsequently attract 
SH2-domain containing molecules for downstream signalling (for a review 
see ref. 5).
Although the exact contribution of either receptor subtype to the different 
biological responses of PDGF is still unclear, accumulating evidence 
suggests a specific role for the a-receptor subunit in early embryonic 
development and tumorigenesis. This notion is supported by the observation 
that both the PDGF A-chain and the a-receptor are already expressed in the 
mouse preimplantation embryo (6-8). In addition, both Pdgfa and Pdfgra 
mRNA are expressed prior to and more abundantly than Pdgfb and Pdgfrb 
mRNA in early mouse postimplantation development (6). Additional 
information concerning the importance of Pdgfra expression during early 
embryonic development comes from studies on Patch mice, which lack the 
Pdgfra gene. Mice carrying this mutation display severe developmental
Introduction
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defects (9-11). Although the impact of Pdgfra expression in later 
development seems to decline, expression of the Pdgfra gene still correlates 
with the development of specific tissues. Glia cell specific Pdgfra expression 
in the developing central nervous system is the most extensively studied 
example (12-14). Tumors arising from glial cells also display a specific 
pattern of PDGFRA expression or contain PDGFRA gene mutations (15-17). 
Another observation that emphasises the relevance of PDGFRA in 
tumorigenesis is its specific expression in highly metastatic murine tumor 
cells (18, 19), malignant ovarian tumors (20) and neuroendocrine tumors 
(21). The regulatory mechanisms underlying the specific expression of the 
PDGFRA gene in development and tumorigenesis are unknown, but they 
will probably reflect a combination of both transcriptional and 
posttranscriptional control. In mouse F9 embryonal carcinoma cells, which 
resemble cells from early embryonic stages, Pdgfra gene expression can be 
induced by the morphogen retinoic acid (RA). This induction of Pdgfra gene 
expression is transcriptionally regulated (22) and occurs also in human 
embryonal carcinoma cells, as shown previously by our group (23). To gain 
more insight in the transcriptional regulation of the PDGFRA gene in 
development and tumorigenesis, we have cloned and characterized exon 1 
and approximately 2 kb of 5’ flanking sequences of the human PDGFRA 
gene. This 5’ flanking region is able to drive luciferase reporter gene 
expression in both human and mouse cells. In addition, this PDGFRA gene 
promoter displays responsiveness to RA and dibutyryl cAMP (Bt2cAMP), 
which are important regulators of embryonal carcinoma cell differentiation.
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Cloning and nucleotide sequence analysis o f  exon 1 and the 5 ' flanking 
region o f the human PDGFRA gene
A 255 nucleotides EcoR1 fragment, representing the 5’ end of the human 
PDGFRA cDNA (kindly provided by Dr. L. Claesson-Welsh, Ludwig 
Institute, Uppsala, Sweden), was used to screen a human genomic DNA 
library resulting in two genomic subclones, pPART101 and pPARP9, that 
contained sequences corresponding to the 5’ end of the human PDGFRA 
cDNA (24, 25). This sequence does not contain the ATG initiation codon 
and, analogous to the closely related c-FMS proto-oncogene (26), reflects the 
non-coding exon 1 of the human PDGFRA gene. The sequence of exon 1 
and approximately 2.1 kb of 5’ flanking DNA is shown in figure 1 in 
comparison with sequences of rat and mouse (27, 28). Not more than 1-kb of 
mouse promoter was available, but comparison between rat and human 
showed that the sequences between -1550 up to +70 are well conserved 
between these species. To test whether the transcription initiation of the 
PDGFRA gene actually starts approximately 30 nucleotides downstream of 
the TATA-motif as suggested by the 5' end of the cDNA, primer extension 
analysis was performed to identify the transcription start site. As shown in 
figure 2, a major primer extension product was detected, corresponding to a 
transcription initiation site at the position marked by the hooked arrow in 
figure 1. This initiation site is located 33 nucleotides upstream of the 5' end 
of the cDNA sequence. This position of transcription initiation makes it very 
unlikely that the transcription start of the PDGFRA gene is directed by the 
TATA-motif, as typically described for the majority of other genes (29).
Results
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hum  AACCCGGTTCTCAACTTAACAGCATGTGGCCCAGCACCCGCTTTTGCCTTTTATTCCGCA
r a t  -------------------------------------------------------------------------AC GC GC -  -  T -------------------------C GCA
hum  CTCTGATTTTTGGGGGGATCGTTTGT- TCCCGCTCATTTTCTACAAACATTACGGTATCC
r a t  -------------------------- GGAG-TCGTTAGCATCCTGTTCATTATCTACAAACATTACGGTATCC
hum  ACAGACCCTCTTTTCTTTGTACCGTATTTCAGACCACCCAGTCTTGTACACACACACACA
m u s GCCGAGCAACCGTTATTTGG-------------------- CACACCGCC----------------- T ---------------CACAAT
r a t  GCTGAGCAACCGTTATTTG---------------------- CACACCATC----------------- T ---------------CACAAT
* * *  * * **  * * * *  **  * * *  * * * * * *
hum  CCACACAAAACAAAAACCCATCATTGTCATATTGGACTCAACAGTTTGCCCAATCCTATT
m u s CCAGCCTTT-CAAAAACCCATCATCTTCCTATTAGACTCCACAGTTT-CCTAATCCCATT
r a t  CCAGCGCTTTCAAAA-CCCATCATCTTCCTATTAGGCTCCACAGTTT-CCTAATCCCATT
hum
r a t
hum
r a t
hum
r a t
hum
r a t
hum
r a t
hum
r a t
hum
r a t
TGTTAGCATTCCGAACAAGGGGCTGTTCATATATTT- GCCTTCAATGATTTC- TGAAGGG
----- AAGCTTTCC------------------------------------------------------------------------------------------ AGGG -
TGCTAGCATTCCGAACAAGGGGCTGTTCATACATTTCGCCTTCAATGATTTCCTGAAGGA
ACATGTGGAAGTAATAGCGAGCGGTGCAGTCACCCAAGCTGAAGATGCAC- GAGAGCGGG
-----------------------------TA----------------------------------- C---------------------------------------------------- G
ACATGTGGAAGTAATTGGGAGCAGGGCAGTCACCCGAGCTGAAGATACACCGAGAGGCGG
TCGCGTAGAAGAACTGCGGCAAT----- GGACCCCCAGCGCACGCCCAGGCGCCCTGTTTTC
TCGCGT--------------------------------------------------------------------------------------GCGCAC--------------
GCGTGCAGAAGGGCATAGGAGAATTGGGACTCTCGGCCCAGCTCCAGGACTCCTCTTCCC
GAGGCTGACATCCCAA-GATCCTGTCCTGGTTAGGCACAGCACCGCGCCCGTTGGAGTAC 
GAACCTGACACCCCAACGGTCCGGTCCCATTTAGGCACAGCACCCGACT— TTCGGGGAA
TTCTCTGTGACTCTCCCCTGTC- -CACTGCACTGTGTCCACCCTCCTGGTGAAGGA
---------------------------------------------------------- CACT----------------------------------------CG-GAAGG-
ACCTCTGTGATTTACCCCAGCCTCAGGGCACTG--------------TC-------------- GTGGTGAAATA
ACCAGTGGTTATTCGACTTTTTGTTATCTACCTGACCGCCTTGTCCATTTTAA---TTCG
TGTGTTGGGGTGGGGTTGAGGGAGA------------------------------------------- AGGATGAAGGATGA
------------------GTGGAATTTAGG-----------------------------------------------------AGGAT------------------
GATAT--GAGTGAGATGGAGGTAGTGTTTGTTTGTTTGTGGTGGTGAGGATAAAGGACTA
hum  AAATAACTAGCAACTATATAGCCCTTCCCCTAAAAGACCCCTAGTTCAAAACGGCGCAAC
m u s AAAGGATTAGCAACTACACGGCACTTTCCCTTAA-GACCCCCAGTTCAAAACGACGCAGC
r a t  AAAGGATTACCAACTACGCGGCACTTTCCCCTAA-GACCCCCAGTTCAAAACGACGCAGC
hum  CGC-TTGGAGATTTCTCCCGAGGGCCCTATTTCTCGTTGGGCCGAGTTTGT--------AGAAG
m u s CGCGTTAGA-ATTTCTCCCCAGGGCCATATTTCTAGCGAGGCCCAGACTGTCTATAGAAA
r a t  CGCATTACG-ATTTCTCCCCAGGGCCATATTTCTAGCGAGGCCCGGACTGCCTATAGAAG
hum  g g a c a t t t c t t g a t t c TAGAt t t a t a t t c t c t c t g g g t a t t a a a t g c a a TTTTGTATGTT
m u s GGATAATT-TGAATTCTAGATTTATATTCGTTTTAGAAATGAGCAGCAATTTTACGTGTA
r a t  GGAGAATT-TGAATTCTAGATTTATATTCGTTTTAGAAATAAGCAGTAATTTTACGTGTG
hum  CCTTTTCTTCTTTTCAAAGAGAATAC-AAAACTATAGC---AGTCTAAGAAAATAACCCC
m u s -------- T-TTTCTTTTCGAAGAGA-TAC-AAAACAATAGC---ACCCCCA----------------- CCCC
r a t  -------- T-TTTCCTTTCGAAGGGAGTACTAAAACTATAGCGACACCCCCC----------------- CTCC
hum  AAAATGGGGAGGCAAACTCATTCTGGAAATGATGGGCTGTTTGTAGTTTCACAAAACCTC
m u s CAAATTGGGAAGTCAACTCATTTTGGAAATGATGG-CTGTTTGTAGTTTCCTGAAACCTC
r a t  CCCATTGAGAAGTCAACTCATTTTGGAAATGATGG-CTGTTTG-AGTTTCATGAACCCTC
1-275
hum  TTTCCCGGCAGAGCACCAAC-ACCTCCCCCTTCCACCACCC--CCCATCCCATCTGGTCT
m u s TTTCCCGGCAGAACGTCAACGACCTCCCCCTTCGGCCCCCCACCCCACCCCATCTGGTTT
r a t  TTTCCCGGCAGAACGTCAAC-ACCTCCCCCTTCAGCCACCC--C-CACCCCATCTGGTTT
1-197 1-175
hum  GCTTCTCCCCGCCCCCCAGTTGTTGTCGAAGTCTGGGGGTTGGGACTGGACCCCCTGATT
m u s GCT--------CCCCCCTCCTCGTTGTTGTTGAAGTCTGGGGGTTGGGACTGGCCCCCCTGATT
r a t  GC---------- CCCCCCCCGTTGTTGTTGTTGAAGTCTGGGG-TTGGGATTGCCCCCCCAGATT
hum  CCC------------CCAACCCCAACAGGAGAATTCAAAAATCAGAGAGCGATGAAGGTGAACGCG hum
m u t -------------------------------------------------------------- AAAAATC------------------------------------------------  m us
r a t  CTCTCGTCGCCCCCCCCCCCAAGAGCATTCAAAAAATAGAGCGC------- AAGTCGAATGCC r a t
hum  CTCCCCTCCCCCGCTGTCGCTGGGAAGCCCCACTCTGTCCAGGTCTGGTTCCTGGAGCAT hum
m u t CT---------------------------------------------------------------- TCTG------------------------------------------------  m us
r a t  CTCCCTTCCCCCACTCGCTCTGGGAAGTGCCTGTC-GCCCAGGTTTGGTTCCTGGAGTGT r a t
hum CAGCGCCCCCTTTCCCTCGCCGGCAGGATCGTTTCCTCCCGACACTGGCCTCTCGCCTTG hum
m u t --------------------------------------- CCATCAAGAT-----------------------------------------------------------------  m us
r a t  CAGCGCCCCCTTTCCCTC-CCGTCAGGATCG------- C---GGCGACT--CTTCGCGCCTGG r a t
1-944
hum  GGCGCAGGGTTT-GGGGCTCAGCTGTCAATTCCAAGGAATTCGTAGGGTTCG---------------- hum
m u t ---GCAGAG -------  G --------------G-------------------C-AGGCATTTGGTAGT---C------------------  m us
r a t  GTGTCTCGGTTTCGTGGCTCAAA---CATCCCGAAAGCTTTCCTAGGGTACCTCGTGTGG r a t
* * * * * ** * * *  *
GCGTAAGAGCAAAAAGCGAAGGCGCAATCTGGACACTGGGAGAT--TCGGAGCGCAGGGA 
GCATAAGAGCAAAAAGCAAAGAAGAGGTCTTGAGCCTGAGAGAG--TCAGAGAGCAAGGA 
GCATAAGAGCAAAAAGCCATGGAGAGGTCT-GAGCCTGAGAGAGGTTCAGAGAGCAAGGA
I-52
G---TTTGAGAGAAACTTTTATTTTGAAGAGACCAAGGTTGAGGGGGGGCTT-ATTTCCT 
G---TCCTAGGGAAACTTTTATTTTGAAGAG-CCAAGGGGGGGGGGGGACTTCATTCCCT 
GGAGTCCAGGGGAAACTTTTATTTTGAAGAGACCA--------GGGGGGGGGGCTTCATTTCCT
GACAGCTATTTAC-TTAGAGCAAATGATTAGTTTTAGAAGGATGGACTAT^CATTGAAT 
GACAGCTATTTACCTTTAAGCAAATGATTAGTTTTTGGAGGATGGACTATAACATTGAAT 
GACAGCTATTTAC- TTTGAGCAAATGATTAGTTTTCGGAGGATG-ACTATAACATTGAAT
CAATTACAAAACGCGGTTTTTGAGCCCATTACTGTTGGAGCTACAGGGAGAGAAACAGAG
CAATTACAAAATGCGGGTTTTGAGCCCATTACTGTTGGAGCTTGAGGGAGAGAAACAAAC
CAATTACAAAATGCGGGTTTTGAGCCCATTACTGTTGGAGCTTGAGGGAGTGAAACAAAC
hum
mr ua t
-ACCCACGCGGCGGGAGGGAACGGAGGGAGAATCAAAAGGCATCCTCCCCCACGAACGCG
--------- ACGC -----------------------------------------------------------------------------------------------------------
GACCCACTCGGAAGGGTGGAATTTA--GAAGGTCAAAATACTTC-TGCCATCCAGATGCA
hum
r a t
G-AGGAGACTGCAAGAGATCATTGGAGGCCGTGGGCACGCTCTTTACTCCATG-TGTGGG
---G G A G -------------- GAG-----------------------------------------------------------------------------------------------
AGAGGAA-CTGTGGGCGAGGACTGGAGGCTTGGGGCTCACTTTTTCCTCCGGGCTATCGG
hum  GAGGCGGTGGTACGATTCCTCAAACGCCCAAGCTTGAGCTTTTTTTGTATGCGA-GATAG
m u t ---------------------------------------------------------- CTAGCCTGAGCGTTTTC---ATATAA-GATAG
r a t  GAGGGCAGGCGTCCCGTAGTCACAC----- CTAGCCTGGGCCTTTTC------ATATGAAGATTG
* ***  **  ** * * * *  ** * * * *  * 
hum  AAGCCAGGGCAACCTCGC-CCAGATAACCCC-GAAAACAAAGGCACGACCAGATAAGTGA
m u t AAG--------------AACCGAGGACCAGATAACCCCCGAAAACAAAGGCAGGACCAGATAAGTGG
r a t  AAG--------------AAACGAGGACCAGATAACTCA-GAAAACAAAGGCAGTACCAGATAAGTGG
hum  CTTC-AAGGGAGTAAAGGTCGTTCTATC----------------GGAGAACGTTC--------CAAACCTAC
m u t CTCCGAAGGGA-TAAAGGTCGTTCTTTCCTTCTTCCGGAGAACATCC------- CAAAGGTAC
r a t  CTCCAAAGGGA--TAAGGTCGTTCTTCC----------------GGAGAACATCCATCCCAAAGGTAC
hum
r a t
hum
r a t
ACATTCATTCCGGAA--TAACATCGGAGGAGAAGGTAGGGGAAAAGAAAAAATGATTTTT
-------------------CTGC-------------------------------GGGGAAGG-ACTGGAA--------------------- G C T T - --
ATTTTC--TTAGCAAACTGACGTAGGAGGAGAAGGTAAGGGAGA-------------------G------------
TGTTTATAAGGGAAGTCCCTGATCAGACT
1-1194
GGAGACGGCTGTTGGACATGCCAGTCCCAACCTG-CCACTTTGGCCATTTTCAGAGTGCG
1-825
Figure 1. Nucleotide sequence of exon 1 and 5’ flanking region of the human, 
mouse and rat PD GFRA  gene (27,28). Asterices indicate identical nucleotides 
conserved between human, mouse and rat. The position of the (human) transcription 
start (+1) is indicated by the hooked arrow. The 5’ and 3’ ends of the promoter 
deletion mutants are represented by vertical lines with nucleotide position.
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A C G T t g m
Figure 2. Primer extension analysis on PDGFRA  cDNA. RNA (50 pg) was reverse 
transcribed using an end-labeled oligonucleotide, complementary to nucleotides 45­
70 of exon 1 (Fig. 1). The products were analysed on a 6% polyacrylamide-ureum 
gel and visualized by autoradiography. t=tRNA, g=Germa II RNA, m=MA-90 RNA 
(both embryonal carcinoma cell lines). As size marker, a parallel nucleotide 
sequence reaction on plasmid DNA, containing exon 1 and 5’ flanking sequences, 
was performed with the same oligonucleotide. Indicated is the nucleotide sequence 
from -4 to +6.
Functional characterization o f the PDGFRA promoter 
To perform a functional analysis of the PDGFRA gene promoter, 
approximately 2 kb of 5’flanking region and part of exon 1 was cloned in 
front of a luciferase reporter gene (see Materials and Methods). In addition, a 
series of 5’ deletion mutants was constructed and the promoter activity of 
these constructs was determined by transient transfection into several 
mammalian cell lines, followed by a monitoring of the luciferase activity. 
Figure 3 shows the results of the transfections into two PDGF a-receptor 
expressing cell lines, RA-differentiated human Tera-2 cells (23) and mouse 
Swiss 3T3 cells (30). It is clear from these data that the 5’ flanking region of 
the human PDGFRA gene is able to drive luciferase gene expression from a
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reporter construct in both human and mouse cells. Thus, the 5’ flanking 
region can act as a functional promoter. The pattern of promoter activity of 
the different 5’ deletion mutants is similar in both human and mouse cells.
Figure 3. Promoter activity of 5’ deletion mutants of the PD GFRA  promoter. A 
series of 5’ promoter deletion mutants, fused to a luciferase reporter gene, were 
transiently transfected into differentiated Tera-2 cells (black bars) or mouse Swiss 
3T3 cells (open bars). Luciferase activity in the cell lysate was determined 24 hrs. 
(Tera-2) or 48 hrs. (Swiss 3T3) post transfection. The luciferase activity was 
normalized to the ß-galactosidase activity of the co-transfected pCH 110 plasmid. 
Values represent mean promoter activity relative to the activity of the -441 /+118 
construct (mean value and sample standard deviation determined from triplicate 
measurements). pSLA4 represents the luciferase vector without promoter insertion 
and the activity of the -944/+118 construct was not determined in Swiss 3T3 cells.
The highest promoter activity was observed in the -441/+118 construct. 
Shortening this construct to -275/+118 dramatically decreased luciferase 
expression, but further 5’ deletions up to -175 restored much of the promoter 
activity. Additional deletions from -175 to -52 reduced the luciferase 
expression to a level < 5% of the maximal expression, but well above 
background (pSLA4). Extending the -441/+118 construct at the 5’ end also 
resulted in a decrease of promoter activity. This complex activity pattern of 
the 5’ deletion mutants suggests that both positive and negative regulating 
elements are involved in basal PDGFRA gene transcription. Still, it can be
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concluded that the human PDGFRA gene 5’ flanking region up to nucleotide 
-441 contains all the elements necessary for high level promoter activity in 
both human and mouse cells. In addition to Tera-2 and Swiss 3T3 cells, 
several other cell lines have been tested for PDGFRA gene promoter activity. 
When transfected with promoter-luciferase constructs, the human malignant 
glioma cell lines U-1242 MG, U-343 MGa 35L (31), mouse normal 
osteoblast-like cells MC3T3-E1 (32) and NIH 3T3 cells showed to be 
positive for luciferase activity, while PDGFRA negative Tera-2 clone 13 
cells show only weak luciferase activity (data not shown). This indicates that 
the promoter constructs are active in a wide variety of PDGFRA expressing 
cells.
An important observation that confirms the specific promoter activity of 
the cloned 5’ flanking region of the PDGFRA gene is the orientation 
dependence of the promoter constructs. When the -2120/+118 promoter 
fragment was cloned in the reverse orientation in front of the luciferase gene, 
promoter activity was abolished, as shown in figure 4.
Figure 4. The PD GFRA  promoter 
activity is orientation dependent. The 
activity of the PDGFRA  gene promoter 
was determined in both the 5’-3’ (­
2120/+118 LUC) and the 3’-5’ (+118/­
2120 LUC) orientation. Values are mean 
± sample standard deviation of triplicate 
determinations.
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RA and cAMP strongly induce PDGFRA promoter activity 
Mouse F9 embryonal carcinoma cells can be differentiated into endoderm- 
like cells by treatment with retinoic acid (RA), or RA in combination with 
Bt2cAMP (33). This differentiation is accompanied by an induction of 
Pdgfra expression, which is completely absent in undifferentiated F9 cells 
(6, 22, 34). Enhanced transcription plays a prominent role in the 
RA/Bt2cAMP-induced Pdgfra expression (22). We have recently shown that 
RA-induced differentiation of human embryonal carcinoma Tera-2 cells is 
also paralleled by an induction of PDGFRA gene transcripts derived from 
the presently described promoter (23). The data in figure 5 demonstrate that 
the above described effects can be explained by RA/Bt2cAMP-induced 
promoter activity. Treatment of transfected Tera-2 cells with RA increased 
the -825/+118 promoter activity 10-fold, and the combination RA/Bt2cAMP 
enhanced promoter activity 22-fold over the unstimulated control levels. In 
contrast to the Pdgfra expression in mouse F9 cells, Bt2 cAMP alone also has 
a pronounced effect on the PDGFRA gene promoter activity in Tera-2 cells. 
The RA or RA/Bt2cAMP-induced PDGFRA gene promoter activity seems to 
be specific for embryonal carcinoma cells; when applied to transfected Swiss 
3T3 cells, no effect of RA or Bt2cAMP could be detected (data not shown).
Figure 5. RA and Bt2cAMP induce 
PD GFRA  promoter activity. The -  
825/+118 LUC construct was 
transfected into undifferentiated Tera- 
2 cells. The cells were treated for 48 
hrs. with the indicated compounds, in 
which theophyline was added to 
stabilise endogenous cAMP (control = 
no treatment). Values represent mean 
± sample standard deviation of 
duplicate determinations. Final 
concentrations: 350 |xM theophylline 
(Th), 5 |jM RA, 100 |jM Bt2cAMP.
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Discussion
The PDGFRA gene belongs to a family of tyrosine kinase receptor genes 
which also includes the PDGFRB gene, c-FMS and c-KIT. These four genes 
are localised on human chromosomes 4 and 5 in a pair-wise manner, and it 
has become evident that they must have originated from a common ancestral 
gene (35). The current data on exon 1, and our previous data on exon 13 to 
16 (23) suggest that the PDGFRA gene is structurally most similar to the 
PDGFRB gene and c-FMS. These three genes are characterized by a non­
coding exon 1, in which they differ from c-KIT. Although the size of the first 
intron of the PDGFRA gene has not been established, the lack of additional 
exons in our exon 1 containing phage DNA indicates that the PDGFRA gene 
probably contains the typical large intron 1 also observed in the other family 
member genes (for an update see ref. 36).
The 5’ flanking region of the PDGFRA gene functions as a promoter, 
based on the following three criteria: 1) when fused to the firefly luciferase 
reporter gene, the 5' flanking sequences are able to drive the expression of 
this luciferase gene; 2) luciferase reporter gene expression is not induced 
when the promoter is in the reverse orientation; and 3) RA and Bt2cAMP 
greatly enhance the luciferase expression of the promoter-luciferase 
constructs. Although this promoter is able to drive luciferase expression in a 
variety of cell lines, it does not necessarily have to be the only promoter of 
the PDGFRA gene. The c-FMS proto-oncogene has two separate promoters 
that confer tissue specific transcription of the gene. One promoter is located 
upstream of the non-coding exon 1, and another is present just upstream of 
exon 2 (37). Due to the non-coding nature of exon 1, transcription initiation 
from both promoters results in identical protein products. Since the
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PDGFRA gene and c-FMS are closely related, this regulatory mechanism 
may also occur in the PDGFRA gene. Currently, however, there are no 
indications for an additional PDGFRA gene promoter just upstream of exon
2. In all the cell lines tested so far, the 6.4 kb PDGFRA mRNA hybridizes 
with an exon 1 specific probe (unpublished observation). However, in 
addition to the 6.4 kb PDGFRA transcript, alternative transcripts are present 
in undifferentiated human embryonal carcinoma cells (23). These transcripts 
initiate from a promoter within intron 12 of the PDGFRA gene. This 
promoter is also capable to drive luciferase reporter gene expression in 
undifferentiated cells (38).
The regulation in embryonal carcinoma cells by RA and Bt2 cAMP is a 
very important characteristic of the PDGFRA promoter. Although 
expression of the PDGFRA gene is affected by a number of growth 
regulating factors, including interleukin-1 (32), PDGF-BB (39), TGFß (30), 
bFGF (40, 41) and RA (6, 22, 23), only for RA it has been shown that it 
affects the transcription of the PDGFRA gene (22). The current study 
confirms this transcriptional effect of RA on the PDGFRA gene expression 
and the synergising effect of Bt2 cAMP. However, in contrast to these data, 
Bt2 cAMP itself also generates a strong induction of promoter activity. The 
exact reason for this discrepancy it not known, but it may reflect the 
difference in the cell system used.
The molecular mechanisms by which RA and Bt2 cAMP increase the 
PDGFRA promoter activity are unknown. The promoter sequence does not 
contain any putative RA receptor or cAMP responsive elements. However, 
the activity of many transcription factors can be modulated by RA and 
Bt2cAMP (42). In particular AP2, for which many putative binding sites are 
available in the human PDGFRA gene promoter, is of interest. It has been 
shown that AP2 activity is induced upon RA differentiation of human
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embryonal carcinoma cells (43). Another transcription factor that could 
mediate the RA inducibility of the PDGFRA gene promoter is GATA. This 
factor is involved in the transactivation by RA of the J6 Serpin gene in 
mouse embryonal carcinoma cells, as recently described (44). Current 
studies are underway to characterize the precise sequence elements involved 
in the RA- and Bt2cAMP-induced promoter activity (see chapter 5).
Two other putative transcription factor binding sites are important for the 
current discussion. The sequenced promoter region contains two PEA3 
consensus sites. High PEA3 expression has been correlated with the 
metastatic potential of tumour cells, similar to high PDGFRA expression 
(18, 19). More interesting, however, is the E2F-like sequence element (45) 
located at nucleotide position -280/-271. Deletion of the region -441 to -275, 
which partially includes this putative E2F site, results in a dramatic decrease 
of promoter activity. In addition it has been hypothesised that the inhibitory 
effect of TGFß on the c-myc promoter is mediated through E2F (46), which 
makes this transcription factor a potential target for the TGFß-regulated 
inhibition of PDGFRA gene expression. Future experiments will have to 
establish the role of E2F in both basal and regulated transcription of the 
PDGFRA gene.
In conclusion, the cloned 5’ flanking region represents a functional 
promoter of the PDGFRA gene, which shows significant conservation 
between human, mouse and rat. The promoter activity can be regulated by 
factors that play an important role in cell growth and differentiation. Thus, 
the cloned PDGFRA promoter region may be a useful tool for studying the 
molecular mechanisms that are involved in PDGFRA gene expression in 
development and in tumorigenesis.
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Materials and Methods
Cell culture
The human embryonal carcinoma cell line Tera-2 clone 13 was maintained 
in a-modification of minimal essential medium (MEM) lacking nucleosides 
and deoxynucleosides, supplemented with 10% fetal calf serum (Gibco 
BRL). Mouse Swiss 3T3 cells were grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% newborn calf serum (Gibco BRL).
Genomic DNA cloning and sequencing
An amplified human genomic DNA library in phage ÀEMBL3 (kindly 
provided by Dr. G. Grosveld, Erasmus University, Rotterdam, The 
Netherlands) was screened with an EcoRI fragment containing nucleotide 1­
255 of the human cDNA clone pSV7d15.1+5 (24). The EcoRl fragment was 
labelled using a random priming labelling kit (Amersham); hybridisation and 
washing were carried out as described previously (23). Using standard 
molecular cloning techniques (47), three out of thirty positively hybridising 
plaques were analysed in more detail. Southern blot analysis of phage DNA 
with the EcoRI probe revealed that all three phages contained an identical 
region of the PDGFRA gene. Phage DNA was subcloned into pBluescript 
SK (Stratagene) and DNA sequence analysis was performed using the 
Pharmacia T7 sequencing kit.
Primer extension analysis
A 26-mer oligonucleotide complementary to the nucleotides 1 to 26 of the 
human PDGFRA cDNA (24) was end-labeled with [y-32P]-ATP using T4
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polynucleotide kinase (Boehringer). Total RNA (50 pg) from the 
differentiated human embryonal carcinoma cell lines Germa II (48) or MA- 
90 (49) and tRNA was ethanol-precipitated together with labelled 
oligonucleotide (5. 105 cpm), and the precipitate was dissolved in 50 ^l 
hybridization buffer (10 mM Tris pH 8.0, 1 mM EDTA and 500 mM NaCl). 
The samples were heated at 95o C for 15 min, incubated overnight at room 
temperature and ethanol-precipitated. Reverse transcription was performed 
in a 30 ^l reaction (50 mM Tris pH 8.3, 75 mM KCl, 3 mM MgCl2 and 10 
mM dithiothreitol) using 200 U Superscript (Gibco BRL) at 37o C for 45 min 
and subsequently at 42o C for an additional 45 min. After treatment with 25 
pg RNAse at 37o C for 30 min, the samples were extracted with phenol­
chloroform, precipitated with ethanol and analysed on a 6% polyacrylamide- 
ureum sequencing gel.
Construction o f promoter-luciferase plasmids
The -2120/+118, -825/+118, -52/+118 PDGFRA promoter fragments were 
amplified from the genomic subclone pPARP9, using the polymerase chain 
reaction (PCR) technique with primers introducing a unique Ncol restriction 
enzyme site within exon 1. PCR fragments were cloned into the T-tailed pT7 
Blue vector (Novagen) and subsequently cloned in front of the luciferase 
gene of the plasmid pSLA4. pSLA4 is a modification of the luciferase gene 
containing plasmid pSLA3 (50) in which the BamHI-Sal1 part of the 
polylinker has been replaced by the BamHI-Sal1 part of the pBluescript SK 
polylinker. All other promoter fragments were isolated from either the - 
2120/+118 or -825/+118 promoter sequences in pT7 Blue, using the 
appropriate restriction enzymes and subsequently cloned in front of the 
pSLA4 luciferase gene. Correctness of the promoter-luciferase constructs 
was confirmed by restriction enzyme analysis and partial sequencing.
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Transfections
Undifferentiated Tera-2 cells were seeded in 0.1% gelatin-coated 6-well 
tissue culture dishes, at a density of 5.103 cells/cm2. The cells were treated 
with 5 ^M retinoic acid (Sigma) for 6 days to induce differentiation before 
transfection. Swiss 3T3 cells were seeded at a density of 3.104 cells/cm2 in a 
6-well tissue culture dish, one day prior to transfection. Both Tera-2 and 
Swiss 3T3 cells were transfected using the calcium-phosphate technique as 
described (47). Transfections were carried out using 5 |lg (Tera-2) or 10 ^g 
(Swiss 3T3) luciferase construct DNA, and a 4 hrs (Tera-2) or 24 hrs (Swiss 
3T3) calcium-phosphate-DNA incubation. The cells were harvested 24 hrs 
(Tera-2) or 48 hrs (Swiss 3T3) post-transfection and luciferase activity was 
assayed in a LKB 1250 luminometer, using a luciferase assay kit (Promega). 
To assess for transfection efficiency, 1 ^g (Tera-2) or 5 ^g (Swiss 3T3) of 
the lacZ gene containing plasmid pCHl10 (Pharmacia) was cotransfected 
with the luciferase construct DNA, while ß-galactosidase activity was 
determined using a chemiluminescent assay as described (51). All 
transfections were performed in several independent experiments, with at 
least two different batches of DNA.
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Promoter haplotype combinations of the 
platelet-derived growth factor a-receptor gene 
predispose to human neural tube defects
Part of this chapter was published as a letter in Nature Genetics, 27 (2001) 215-218, 
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Abstract
Neural tube defects (NTDs), including anencephaly and spina bifida, are 
multifactorial diseases that occur with an incidence of 1 in 300 births in the 
United Kingdom (1) . Mouse models have indicated that deregulated 
expression of the gene encoding the platelet-derived growth factor a- 
receptor (Pdgfra) causes congenital NTDs (2-4), whereas mutant forms of 
Pax-1 that have been associated with NTDs cause deregulated activation of 
the human PDGFRA promoter (2, 5). There is an increasing awareness that 
genetic polymorphisms may have an important role in the susceptibility for 
NTDs (6). Here we identify five different haplotypes in the human PDGFRA 
promoter, of which the two most abundant ones, designated H1and H2a, 
differ in at least six polymorphic sites. In a transient transfection assay in 
human bone cells, the five haplotypes differ strongly in their ability to 
enhance reporter gene activity. In a group of patients with sporadic spina 
bifida, haplotypes with low transcriptional activity, including H1, were 
under-represented, whereas those with high transcriptional activity, 
including H2a, were over-represented. When testing for haplotype 
combinations, H1 homozygotes were fully absent from the group of sporadic 
patients, whereas H1/H2a heterozygotes were over-represented in the groups 
of both sporadic and familial spina bifida patients, but strongly under­
represented in unrelated controls. Our data indicate that specific 
combinations of naturally occurring PDGFRA promoter haplotypes strongly 
affect NTD genesis, while the importance of disturbed PDGFRA 
transcription in this congenital defect is underlined by the additional finding 
of a mutant H2 haplotype.
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Introduction
Neural tube defects (NTDs) including anencephaly and spina bifida are among 
the most common human birth defects, with an incidence varying from 1 in 
3000 births in Finland to 1 in 300 births in UK and Ireland (1). 
Epidemiological data show that most NTDs occur as a consequence of a 
complex interaction between environmental and a variety of predisposing 
genetic factors, which is indicative for a multifactorial process (7). The 
observed effects of folic acid and/or myo-inositol suppletion on neural tube 
closure, combined with risk factors such as paternal exposure to chemicals and 
radiation, suggest an important role for the environment. On the other hand, 
the occurrence of familial NTDs and the increased risk observed for children 
of affected parents suggest the existence of predisposing genetic factors (8, 9). 
The heritability in human NTDs, which can be defined as the relative 
contribution of genetic factors, has been estimated to be approximately 60 
percents (7). A useful model to explain such multifactorial inheritance is the 
so-called liability/threshold model. According to this model discontinuous 
phenotypes can be explained by assuming that the sum of adverse genetic 
and/or environmental factors must exceed a certain threshold before an 
abnormal phenotype such as NTDs becomes manifest (10). In the case of spina 
bifida, a severe form with open lesions exists (spina bifida aperta) and a less 
severe form in which the lesion is covered with skin (spina bifida occulta). 
Particularly this latter form is not always recognized and in fact it is has been 
suggested that latent lesions exist in at least 5% of the total adult human 
population (11, 12).
Several studies on mouse models with NTDs have provided evidence for 
the involvement of specific genes which function during embryonic neural 
tube development. However, in mice mutations in such genes generally cause
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syndromic effects, while in humans NTDs are usually not associated with 
other malformations or defects (13). This observation limits the usefulness of 
such mouse models for understanding genetic factors involved in NTDs in 
humans. One of the genes that has been studied in particular for its role in 
NTDs is that encoding the platelet-derived growth factor a-receptor 
(PDGFRA). This receptor binds almost all isoforms of the growth factor 
PDGF, and is expressed particularly in the mesoderm and neural tube during 
embryonic development (14). Mice with a targeted null mutation in the 
PDGFRA gene and also so-called Patch mutant mice with a natural deletion of 
the chromosomal region that includes the PDGFRA gene both show severe 
spina bifida combined with embryonic lethality in their homozygous form (3, 
4). Mice heterozygous for the Patch deletion show spina bifida only in 
combination with the so-called undulated mutation in the Pax-1 gene (2). We 
have recently shown that Pax-1 acts as an upstream transcriptional regulator of 
the PDGFRA gene, suggesting that the observed phenotype is largely 
determined by dose effects in PDGFRA gene expression (5). In functional 
studies we have shown that the undulated Pax-1 mutant as well as a mutant 
human PAX-1 obtained from a patient with spina bifida (15) shows disturbed 
transcriptional activity (5), indicating that deregulated PDGFRA transcription 
might be one of the factors that contributes to the occurrence of NTDs. 
Subsequent low or high PDGF signalling may lead to either premature 
differentiation or a prolonged undifferentiated, proliferative status of neural 
glia and cartilage precursors (16, 17).
There is an increasing awareness that genetic polymorphisms may play an 
important role in determining susceptibility to NTDs (6). In the present study 
we have studied a panel of both sporadic and familial patients with spina 
bifida for polymorphisms in both the coding regions and the promoter 
sequences of the human PDGFRA gene. We have previously cloned and
52
PDGFRA haplotypes predispose to NTDs
characterised the human PDGFRA promoter. We showed that the 2 kb region 
immediate upstream of exon 1 controls transcriptional regulation of this gene 
(18). When tested in transgenic mice, this region appeared to be responsible 
for the spatio-temporal expression pattern of PDGFRA during development, 
including the sclerotome (19). Comparison with the corresponding sequences 
of the mouse and rat gene showed particular conservation in the first 1.5 kb 
region of the promoter (20, 21). Our current studies show that the human 
PDGFRA promoter has two major haplotypes that differ in as many as 6 
polymorphic sites within this 1.5 kb region, in addition to a number of variants 
that differ only by a single nucleotide. Homozygotes for haplotype 1 were 
detected in controls and in patients with familiar spina bifida, but not in 
patients with sporadic spina bifida. Moreover, heterozygotes for various 
haplotype combinations were significantly more abundant in the patient 
population. Combined with functional studies in osteosarcoma cells that show 
strongly divergent activity of the various promoter haplotypes, these studies 
indicate that genetic variation in PDGFRA expression may be a major 
contributor to the risk factors for neural tube defects.
Results
We carried out single-stranded conformation (SSC) analysis on the 2-kb 
region upstream of the transcription initiation site of human PDGFRA (18). 
In transgenic mice, this region is known to be responsible for the spatio­
temporal expression pattern of this gene during development (8). We 
performed analysis on 76 patients with sporadic spina bifida, 49 patients 
with familial spina bifida and 77 unrelated controls. SSC analysis revealed 
the presence of at least eight polymorphic sites in this promoter region,
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whereas subsequent sequencing of PCR products and cloning of genomic 
promoter sequences revealed the existence of five different haplotypes of the 
PDGFRA promoter. These haplotypes can be divided into two subfamilies, 
designated H1 and H2, that differ in at least five positions, including a two- 
nucleotide deletion/insertion in the noncoding region of exon 1 (Fig. 1). 
Additional polymorphisms may exist further upstream (9). We found four 
H2 variants, designated H2a-ô, of which H2ß-ö differ by only a single 
nucleotide from H 2a . In addition we found in one patient a point mutation, 
giving rise to an additional mutant H2 variant designated H2aM. Analysis of 
the control individuals revealed that 30.5% of the haplotypes were of type 
H1 and 57.1% of type H2a, with minor contributions of H 2a-ô (Fig. 2a). 
The overall haplotype distribution in the group of familial spina bifida 
patients was not different from that of the control group, but the group of 
sporadic patients showed a 40% reduction in H1 haplotypes, combined with 
an over-representation of H 2a and H2ß haplotypes.
We tested these groups for the presence of specific PDGFRA promoter 
haplotype combinations, and found that H1 homozygotes were fully lacking 
in the group of sporadic patients, whereas H2a /H2a heterozygotes were 
over-represented in this group (Fig. 2b). Heterozygotes of the two most 
abundant haplotypes, H1 and H2a, were significantly under-represented in 
the control group compared with Hardy-Weinberg equilibrium, whereas 
such heterozygotes were over-represented in the groups of both sporadic and 
familial patients (Fig. 2c). Improper proliferation and differentiation of the 
mesodermal cartilage precursor cells that form the neural arches are major 
events in the genesis of spinal NTDs (3, 4, 22, 23). We therefore tested the 
activity of the various promoter haplotypes by transient transfection of 
promoter haplotype-luciferase constructs into human U-2 OS osteosarcoma 
cells, which are an in vitro model system for bone formation during
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development. We observed strong differences in transcriptional activity 
between the various haplotypes, with an up to sixfold higher activity of 
haplotypes H 2a and H2ß compared with that of H1, H2y and H2Ô (Fig. 3). 
The two haplotypes with high activity are those that were found to be over­
represented in sporadic spina bifida patients, whereas those with low activity 
were found to be under-represented in these patients (Fig. 2a). The frequency 
of the high-activity haplotypes H 2a and H2ß, compared to that of the low- 
activity haplotypes H1, H2y and H2Ô, showed a strongly significant 
difference between the sporadic spina bifida patients and the control group 
(p<0.01). The mutated H2aM haplotype, however, showed an intermediate 
transcriptional activity compared to the H2 wild-types with high and low 
activity. These data provide a direct correlation between the distribution of 
haplotypes in a patient population and a functional biochemical parameter of 
these haplotypes in vitro.
in 01 * w o <b <b
M 1 2 3 4 5 6 7
Nucleotide changes for each haplotype:
1 A G A G  C A C T  -GA
2a A A G C C G C G  +GA
2ß A A A C C G C G  +GA
2y A A G C  C G A G  +GA
28 A A G C  A G C G  +GA
2 M G A G C  A G C G  +GA
Figure 1. Promoter haplotypes resulting from polymorphisms and a mutation in the 
—1,589/+118 nucleotide sequence of PD GFRA  (18). Top, the identified eight 
polymorphic sites and the mutation are indicated together with their corresponding 
nucleotide position. Bottom, the identified haplotypes and mutant form (H1, H2a, 
H2ß, H2y, H25 and H2aM) are indicated together with their nucleotide sequence at 
the polymorphic or mutant sites.
EXON 1
55
Chapter 3
A
FAMILIAL SPORADIC CONTROL
H1 31 31.6% 28 18.4% 47 30.5%
H2a 54 55.1% 104 68.4% 88 57.1%
H2ß 6 6.1% 13 8.6% 7 4.5%
H2y 3 3.1% 4 2.6% 6 3.9%
H2Ö 4 4.1% 3 2.0% 6 3.9%
B
H1 H 2a H2ß H 2y H2S
H1 T=15 (7.4%) 
C=11 (14%) 
S=0 (0%) 
F=4 (8%)
H 2a T=65 (31.6%) 
C=18 (23%) 
S=26 (34%) 
F=20 (40%)
T=79 (39.1%) 
C=31 (40%) 
S=33 (43%) 
F=15 (30%)
H2ß T=7 (3.4%) 
C=4 (5%) 
S=1 (1.3%) 
F=2 (4%)
T=15 (7.4%) 
C=3 (4%) 
S=9 (12%) 
F=3 (6%)
T=1 (0.5%) 
C=0 (0%) 
S=1 (1.3%) 
F=0 (0%)
H 2y T=2 (1%) 
C=0 (0%) 
S=1 (1.3%) 
F=1 (2%)
T=7 (3.4%) 
C=4 (5%) 
S=2 (2.6%) 
F=1 (2%)
T=2 (1%) 
C=0 (0%) 
S=1 (1.3%) 
F=1 (2%)
T=1 (0.5%) 
C=1 (1.3%) 
S=0 (0%) 
F=0 (0%)
H2S T=3 (1.5%) 
C=3 (4%) 
S=0 (0%) 
F=0 (0%)
T=2 (1%) 
C=1 (1.3%) 
S=1 (1.3%) 
F=0 (0%)
T=0 (0%) 
C=0 (0%) 
S=0 (0%) 
F=0 (0%)
T=0 (0%) 
C=0 (0%) 
S=0 (0%) 
F=0 (0%)
T=4 (2%) 
C=1 (1.3%) 
S=1 (1.3%) 
F=2 (4%)
C
FAMILIAL SPORADIC CONTROL
H1\H1 8.2% 10.0% 0.0% 3.4% 14.3% 9.3%
H1\ H2a 40.8% 34.8% 34.2% 25.2% 43.4% 34.8%
H2a\ H2a 30.6% 30.4% 43.4% 46.8% 40.3% 32.6%
Obs. Exp. Obs. Exp. Obs. Exp.
Figure 2. Distribution of the different PD G FRA  promoter haplotypes in a group of 
49 familial spina bifida patients, 76 sporadic spina bifida patients and 77 control 
individuals. Sporadic patients had no first-, second- or third-degree relative with 
neural tube defects, whereas familial patients had at least one known affected 
relative within the third degree. Controls were unrelated to any of these patients. A) 
The distribution of the various haplotypes over the three groups is indicated in both 
absolute numbers and percentages, assuming diploid chromosome numbers. Based
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2
on % analysis, H1 haplotypes are significantly under-represented in the sporadic 
patients compared with controls (p<0.01;%2 =6.05). B) The distribution of haplotype 
combinations in the three groups is indicated. The total (T) number of individuals 
identified with a specific haplotype combination is indicated in both absolute 
numbers and percentages, as well as for the group of controls (C), sporadic patients 
(S) and familial patients (F). Note that H1 homozygotes are absent from the group of 
sporadic patients (p<0.01 compared with controls; %2 =11.7), whereas in this group 
H2a /H2ß heterozygotes have a tendency towards over-representation (p<0.1 
compared with controls; %2 =3.34). C) The observed distribution of combinations of 
the two major haplotypes (H1 and H2a) in the investigated groups (Obs.) is 
compared with the expected Hardy-Weinberg equilibrium (Exp.). The observed 
distribution of H1 homozygotes, H1/H2a . heterozygotes and H2a homozygotes 
corresponds in all three groups to 77-78% of all haplotype combinations present. 
When considering specific haplotype combinations, H1 homozygotes were 
significantly higher in both controls (p<0.01; %2 =11.7) and familial patients 
(p<0.02; %2 =6.4) compared to sporadic patients. Moreover, H1/H2a heterozygotes 
were significantly more abundant in familial patients compared with controls 
(p<0.05; %2 =4.3). When testing the various groups for significant deviation of 
genotype frequencies from Hardy-Weinberg equilibrium according to a three-allele 
%2 analysis (with alleles H1, H2a, and the pooled group H2ß+H2y+H2§), we 
observed a significant deviation in controls (p<0.05; % =7.91 with three degrees of 
freedom), with a significant deficit of heterozygotes (p<0.01; FIS=+0.248) 
according to the U-test (28). The group of sporadic patients showed significant 
deviation from Hardy-Weinberg equilibrium (p<0.05; %2 =8.34) with a non­
significant excess of heterozygotes (FIS= -0.089), whereas we observed no 
significant deviation from equilibrium in the group of familial patients.
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□  Hl BH 2a EH2ß BH2y BH2ö IHH2M
Figure 3. Distribution of promoter activity of transfected 5 ' PD GFRA  haplotypes in 
U-2 OS and SAOS cells. Actvity is presented as the ratio of luciferase and ß- 
galactosidase activities, including standard deviation. Repeated transfections were 
carried out in duplicate with different batches of DNA. A similar activity pattern of 
haplotypes was observed in the HOS human osteosarcoma cell line (not shown).
Discussion
Our current results show that combinations of naturally occurring PDGFRA 
promoter haplotypes contribute to the adverse factors that eventually 
determine the manifestation of spina bifida in humans, while in individual 
cases also promoter mutations can be involved. The observation that the H2 
haplotype shows multiple variants, in contrast to H1, may indicate that H1 
has only recently been introduced in the population investigated. The 
observation that H1/H2a heterozygotes are under-represented in the control 
population could indicate that H1 and H 2a haplotypes are not randomly
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mixed in the population, as has been shown for promoter haplotypes of the 
ß2-adrenergic receptor (26). This possibility seems unlikely, however, in the 
light of the over-representation of such heterozygotes in the patient 
population. Our results therefore indicate that, most likely in combination 
with other adverse factors, H1/H2a heterozygotes have an increased risk for 
malformations resulting in either embryonic lethality or NTDs. The 
observation that no H1 homozygotes were found in the group of sporadic 
patients may indicate that this haplotype combination selects against the 
formation of spina bifida. No such protective effect was observed in the 
group of familial patients, indicating that in these patients additional adverse 
factors are involved for which H1 homozygosity cannot compensate.
Various mouse models have indicated that aberrant expression of Pdgfra 
may result in spina bifida. Mice with a targeted null mutation in Pdgfra and 
Patch mutant mice, which contain a natural deletion of the chromosomal 
region that includes Pdgfra, both show severe spina bifida combined with 
embryonic lethality in their homozygous form (3, 4). We have previously 
shown that gain-of-function mutations in the gene encoding Pax-1, an 
upstream transcriptional regulator of Pdgfra, are also associated with spina 
bifida (5, 15). It has been proposed that reduced PDGF signalling during 
development may lead to premature differentiation of the neural glia and 
cartilage precursor cells, whereas upregulated PDGF signaling may result in 
a prolonged, undifferentiated, proliferative status of these cells (16, 17, 25), 
in both cases resulting in improper closing of the neural tube. Studies on the 
human, mouse and rat PDGF a  -receptor promoter have provided evidence 
for the involvement of several spina bifida associated transcription factors, 
such as GATA-4 (27), PAX3 (28), Pax-1 (5) and C/EBPs (29), in 
transcriptional activation of this gene. Further investigations are needed to 
indicate whether these and other transcription factors are expressed in the
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relevant cell types and are able to activate the human PDGFRA promoter in a 
haplotype-specific manner (9).
The observed correlation between haplotype variant activity in U-2 OS 
cells and their over- or under-representation in spina bifida patients is 
indicative for the relevance of these functional data, but does not explain 
why H1/H2a heterozygosity predisposes to spina bifida. H 2a homozygosity 
seems to be a neutral factor in the genesis of NTDs. As is also indicated by 
the H2aM mutant haplotype, transcriptional deregulation seems an important 
event during human NTD genesis. In line with this observation one could 
hypothesise H1/H2a to be a negative factor for proper transcriptional 
regulation. It is known from embryonic developmental processes in lower 
organisms that promoters on different chromosomes may physically interact 
and can have a combined activity that is different from the average activity 
of the two promoters (25). Little is known about similar processes in 
mammals (26), particularly because in vitro detection assays for such so- 
called ‘transvection’ phenomena are still lacking. Differences in temporal 
expression patterns could provide another explanation, since the combination 
of two promoters with a shift in temporal expression may give rise to a 
prolonged PDGFRA expression that might have negative effects on normal 
embryonic development. It will be worth investigating if such processes may 
underlie the observed improper matching of H1 and H2a haplotypes of the 
PDGFRA promoter, resulting in enhanced embryonic lethality and NTDs.
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Methods
Automated sequencing
DNA sequences of PCR products and DNA constructs were analysed using 
the ABI310 automated sequencer according to the manufacturer’s protocols.
Cell culture
U-2 OS cells were seeded at a density of 5.0x104 cells/cm2 and grown in 
Dulbecco’s MEM/nutrient mix F12 (1:1) supplemented with 10% (v/v) fetal 
calf serum (Gibco) and NaHCO3 (44 mM) in a 7.5% CO2 atmosphere at 
37°C.
Haplotype cloning
PCR products of the 5' flanking sequences of PDGFRA were obtained using 
Pfu polymerase with proofreading (New England Bio-labs), and were ligated 
and cloned using a PCR cloning vector (Invitrogen). Clones were analysed 
and Pstl/Ncol (Fermentas) restriction fragments were subsequently ligated 
into the pSLA4 luciferase reporter vector (Promega).
SSC analysis
DNA samples of 76 sporadic patients, 49 familial NTD patients and 77 
control individuals were analysed by PCR (Fermentas) and subsequent SSC 
analysis with the Phast System (Promega) according to the manufacturer’s 
protocols. SSC analysis was carried out at 4° C on native gels with native 
buffer strips using 0.3 ^l PCR reaction mix containing the amplified 
fragment for each sample.
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Transfection, luciferase and ß-galactosidase assays
The —1589/+118 PDGFRA promoter haplotype constructs were each 
transiently transfected into U-2 OS cells using the calcium phosphate 
coprecipitation method (27), in 10 cm2 wells seeded with 3.5x105 U-2 OS 
cells one day before transfection. Luciferase activity was detected 48 hrs 
post-transfection (Luciferase assay kit, Promega). The activity of 1 ^g 
transfected luciferase construct was corrected for transfection efficiency by 
measuring the ß-galactosidase activity obtained from co-transfected SV40- 
driven lacZ gene construct PCH110 (50 ng; Promega).
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Altered regulation of PDGFRA transcription in 
vitro by spina bifida-associated mutant Paxl
proteins
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Abstract
Mouse models show that congenital neural tube defects (NTDs) can occur as 
a result of mutations in the platelet-derived growth factor a-receptor gene 
(Pdgfra). Mice heterozygous for the Pdgfra mutation Patch, and at the same 
time homozygous for the undulated mutation in the Paxl gene, exhibit a 
high incidence of lumbar spina bifida occulta, suggesting a functional 
relation between Pdgfra and Paxl. Using the human PDGFRA promoter 
linked to a luciferase reporter, we show in the present paper that Pax1 acts as 
a transcriptional activator of the PDGFRA gene in differentiated Tera-2 
human embryonal carcinoma cells. Two mutant Pax1 proteins carrying either 
the undulated mutation or the G ln^H is mutation previously identified by us 
in the PAX1 gene of a patient with spina bifida, were not or less effective, 
respectively. Surprisingly, Pax1 mutant proteins appear to have opposite 
transcriptional activities in undifferentiated Tera-2 cells as well as in the U-2 
OS osteosarcoma cell line. In these cells the mutant Pax1 proteins enhance 
PDGFRA promoter activity whereas the wild-type protein does not. The 
apparent upregulation of PDGFRA expression in these cells is the first 
reported gain-of-function phenomenon associated with mutations in Pax 
genes. The altered transcriptional activation properties correlate with altered 
protein-DNA interaction in band-shift assays. Our data provide additional 
evidence that mutations in PAX1 can act as a risk factor for human neural 
tube defects and suggest that the PDGFRA gene is a direct target of PAX1. 
In addition, the results support the hypothesis that deregulated PDGFRA 
expression may be causally related to NTDs.
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Pax1 and PDGFRA
Neural tube defects (NTDs) form a major group of congenital malformations 
with an average incidence of approximately 1 per 1000 pregnancies. NTDs 
are generally accepted to represent multifactorial traits with genetic and 
environmental factors contributing to their aetiology. To date, very little is 
known about the identity of the genetic factors involved, although several 
candidate genes have emerged from studies of mutant mouse strains which 
display NTDs or related malformations (1).
Pax1 is a member of the Pax gene family of developmental control genes 
which encode transcription factors that contain a DNA binding 'paired 
domain' (2). The gene is highly conserved between species and there is a 
100% conservation between the paired domains of murine Pax1 and its 
human counterpart PAX1 at the amino acid level (3, 4). The mouse mutant 
undulated (un) contains a recessive missense mutation in the paired domain 
of the Pax1 gene which results in a protein with altered DNA binding 
affinity and transcriptional activity (5, 6). Analysis of the undulated 
phenotype has shown that Pax1 is essential for normal vertebral development 
(7, 8). Although these mice do not display spina bifida, a high incidence of 
lumbar spina bifida was observed in double mutants resulting from a cross 
between undulated and Patch (Ph), indicating that Pax1 can be involved in 
NTD aetiology (9). Moreover, we recently identified a missense mutation in 
the paired domain of the human PAX1 gene in a patient with spina bifida, 
suggesting that mutations in this gene may also play a role in human NTDs
(10).
The platelet-derived growth factor receptor alpha gene (Pdgfra) is located 
within a 50-400 kb region that has been deleted in the mouse mutant Patch
Introduction
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(11). Heterozygotes are characterized by patches of white fur and have an 
intact axial skeleton, whereas homozygous embryos display occult spina 
bifida involving the entire spinal column and die during early embryogenesis
(12). Targeted inactivation of the murine Pdgfra gene results in mice with 
spina bifida at the thoracic level (13). Recently, we have cloned and 
characterized the human PDGFRA promoter and shown that the 5' flanking 
region together with the non-coding exon-1 acts as a functional promoter for 
the 6.4 kb full length receptor transcript (14, 15).
The observed NTD phenotype of the double mutant mice with the 
(un/un,Ph/+) genotype, suggests an interaction between Pax1 and Pdgfra. 
This suggestion is supported by the observation that Pdgfra expression 
overlaps with Pax1 expression during embryonic development, particularly 
in the sclerotome which forms the vertebral column (9). Pdgfra-mutated 
mouse strains show no effect on Pax1 expression in the segmented paraxial 
mesoderm (13). Therefore, Pax1 may act as an upstream regulator of Pdgfra.
Consequently, both Pax1 and Pdgfra are considered to be candidate genes 
for spina bifida. In the present study we show that the PAX1 mutation 
previously identified in a patient with spina bifida, affects the DNA binding 
properties of the protein. In addition, we demonstrate that wild-type and 
mutated Pax1 proteins have different effects on PDGFRA transcription in 
Tera-2 human embryonal carcinoma cells in a differentiation-dependent 
manner and in the U-2 OS osteosarcoma cell line. The data obtained are 
discussed within the hypothesis that deregulated PDGFRA transcription may 
be causally related to NTDs, including spina bifida.
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Production o f wild-type and mutant Pax1
In order to test the functionality of the different Pax1 proteins, full-length 
murine Pax1 proteins were generated in an in vitro transcription/translation 
system. In addition to the wild-type Pax1 protein (wt-Pax1), two NTD- 
associated mutant proteins were also synthesized. The first one (sb-Pax1) 
contained the G ln^H is substitution that was previously identified by us at 
position 42 of the paired domain in a patient with spina bifida (10). The 
second mutant protein (un-Pax1) contains the G ly^Ser replacement at 
position 15 of the paired domain that is known to be responsible for the 
undulated phenotype in mice (5).
In order to show that full length proteins are synthesized, we performed a 
Western blot analysis. For this purpose polyclonal antibodies were generated 
recognizing the C-terminal part of Pax1, which is not affected in the mutated 
proteins. These antibodies detect a protein of the predicted size of 40 kDa in 
protein extracts of the developing vertebral column of 13.5 days old mouse 
embryos (Fig. 1). In contrast, no Pax1 protein was detectable in the extract of 
the Un mouse embryo in which the Pax1 gene is deleted (7), showing that 
the antibodies are Pax1-specific. Using these antibodies the three in vitro 
generated Pax1 proteins are detectable with the same mobility as the wild­
type Pax1 protein (Fig. 1), thereby demonstrating that full length proteins 
have been synthesized.
Results
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pc ne wt sb un
49.5 —
32.5 —
Figure 1. In vitro transcription and translation of Pax1 and derived mutants. The in 
vitro transcription/translation products of wild-type Pax1 (wt), spina bifida-derived 
Pax1 (sb) and undulated  Pax1 (un) were detected on Western blot by a specific anti- 
Pax1 antibody. As a positive (pc) and negative control (nc) total protein extract from 
the developing vertebral column of 13.5 day old wild-type and a homozygous 
undulated shorttail (UnS) embryos were used, respectively. In UnS mutant mice the 
P a x l gene has been deleted completely. The antibody detects a predicted band of 
approximately 40 kDa, which is not present in the negative control. No Pax1 was 
detected in the transcription/translation lysate (not shown).
Binding properties o f wild-type and mutant Pax1
To study the DNA binding ability of the different Pax proteins, 
electrophoretic mobility shift assays (EMSAs) were carried out using the 
PRS4 consensus binding sequence for Pax1 (6). Figure 2 shows that with wt- 
Pax1 the formation of a specific DNA-protein complex causes a clearly 
detectable bandshift. Using the antibody Pax1 was identified within this 
complex (not shown). In contrast no bandshift was detected with un-Pax1, 
which is in accordance with the earlier work of Chalepakis et al. (6). In this 
context one should realise, however, that un-Pax1 was shown to be able to 
bind to other sequences. Remarkably, sb-Pax1 induces a shift, but with a
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different mobility from that induced by wt-Pax1. Since both proteins without 
DNA have a similar mobility (Fig. 1), sb-Pax1 apparently binds to the DNA 
sequence in a slightly different conformation compared to wt-Pax1. These 
altered binding characteristics may have consequences for the proper 
functioning of the Pax1 transcription factor.
Ly un wt sb SC 0
• -* ?
Figure 2. Electrophoretic mobility shift assays with Pax1 and derived mutants. In  
vitro transcription/translation products of wild-type Pax1 (wt-Pax1), spina bifida- 
derived Pax1 (sb-Pax1) and undulated  Pax1 (un-Pax1) were assayed for binding 
activity on the PRS4 probe derived from the e5 site in the Drosophila even-skipped 
promoter. The lanes Ly, un, wt, sb, SC, and 0, correspond to incubation of the probe 
with reticulocyte lysate, un-Pax1, wt-Pax1, sb-Pax1, wt-Pax1 + unlabeled PRS4 
probe in a 500-fold excess, and H2O, respectively. The Pax1 bands are indicated 
with arrows. Non-specific bands are indicated with asterices.
Effect o f wild-type and mutant Pax1 on PDGFRA transcription 
As already mentioned, the phenotype of (un/un,Ph/+) double mutants 
suggests that Pax1 and Pdgfra participate in the same functional cascade. 
One possibility is that Pax1 acts as an upstream regulator of Pdgfra. To 
assess the effect of the various Pax1 proteins on the transcriptional activity
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of the PDGFRA promoter, plasmids encoding these proteins were 
cotransfected with the -944/+118 human PDGFRA promoter linked to the 
luciferase gene. Transfection studies were carried out in Tera-2 cells. In their 
undifferentiated state, these embryonal carcinoma (EC) cells resemble cells 
in early stages of human development. Only after in vitro differentiation by 
retinoic acid (RA) these cells express a functional PDGFRA (20). No 
endogenous expression of PAX1 was observed in both Tera-2 EC and Tera-2 
RA cells by RT-PCR analysis (not shown). Since Pax1 is one of the earliest 
markers for sclerotome differentiation, additional transfection experiments 
were carried out in the U-2 OS human osteosarcoma cell line. These cells 
have endogenous PDGFRA expression (21). Figure 3a shows that wt-Pax1 
induces up to three-fold stimulation of promoter activity in Tera-2 RA cells. 
Un-Pax1 is ineffective in increasing promoter activity in these cells, while 
sb-Pax1 has intermediate activity. These results show that an intact Pax1 
protein is essential to efficiently promote PDGFRA transcription in Tera-2 
RA cells. Interestingly, in Tera-2 EC cells a significant increase in activity of 
the PDGFRA promoter was observed with sb-Pax1, whereas only little effect 
was seen with un-Pax1 (Fig. 3b). Figure 3c shows that in U-2 OS sb-Pax1 
and un-Pax both induce promoter activity, the latter being the most potent 
activator under these conditions, while wt-Pax is again ineffective. These 
results show that wild-type and mutated Pax1 proteins can have opposing 
transcriptional activities, depending on the specific transcriptional 
background in different cell types. Moreover it shows that mutations in Pax1 
can result in a gain-of-function with respect to transcriptional activity of the 
protein.
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Figure 3. Regulation of transcriptional activity of the PD GFRA  promoter by Pax-1 
and derived mutants. The activity of the -944/+118 promoter luciferase construct 
(P1) is regulated differently by wild-type Pax1 (wt), spina bifida-derived Pax1 (sb) 
and undulated Pax1 (un) in retinoic acid-differentiated Tera-2 RA cells (A, hatched 
bars), undifferentiated Tera-2 EC cells (B, blanc bars) and U-2 OS (C, black bars). 
Values are presented as mean promoter activity relative to the activity of the - 
944/+118 clone cotransfected with the expression construct without a Pax1 insert, 
which was set to 1. Error bars indicate the sample standard deviation after 4 
luciferase/beta-galactosidase measurements.
Discussion
In the present study we have shown that the G ln^H is mutation in PAX1, 
previously identified by us in a patient with spina bifida, is associated with 
altered in vitro DNA binding properties of the full length protein. Our results 
suggest that this mutation affects the functionality of the PAX-1 protein and, 
therefore, may have contributed to the phenotype observed in the patient.
In addition, we investigated the influence of Pax1 on PDGFRA 
transcription. We showed that wild-type Pax1 protein enhances PDGFRA 
transcription in differentiated Tera-2 human embryonal carcinoma cells (Fig. 
3 a), while two mutant Pax1 proteins carrying either the undulated mutation
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(un-Pax1) or the G ln^H is mutation (sb-Pax1), were not or less effective, 
respectively. Surprisingly, Pax1 mutant proteins appear to have opposite 
transcriptional activities, depending on the cell differentiation status in the 
Tera-2 cells, as well as in the U-2 OS osteosarcoma cell line. (Fig. 3b-c). 
These activities of the mutated Pax-1 proteins are the first examples of 
mutations in a Pax gene that can be associated with a gain-of-function 
phenomenon. This could have yet unknown consequences during embryonic 
development and may play a role in the pathogenic mechanism underlying 
specific types of NTD.
The above observations support the hypothesis that PAX1 is an upstream 
regulator of PDGFRA and that deregulated PDGFRA transcription may be 
causally related to spina bifida. In this way it can be explained that spina 
bifida is not only observed in the targeted Pdgfra null mutation (13) and in 
homozygous Patch (Ph/Ph) mice (12), but also in Patch (Ph/+) 
heterozygotes with an additional Pax1 mutation (un/un) (9). Accordingly, the 
spina bifida phenotype in the patient carrying the sb-Pax1 mutation may be 
the result of impaired regulation of PDGFRA transcription. In this context 
the gain-of-function phenomenon could be very important for effectively 
deregulating PDGFRA expression and thus could contribute as well to the 
spina bifida phenotype. It is well realized, however, that NTDs including 
spina bifida are a multifactorial trait, and that other genes and/or 
environmental influences are likely to be involved.
We have previously shown that the human PDGFRA gene is able to give 
rise to multiple mRNA products, as a consequence of alternative promoter 
use and alternative splicing (18,22). In Tera-2 EC cells a 1.5 kb and a 5.0 kb 
transcript have been identified, which are transcribed from a promoter in 
intron 12 of the gene (18). In contrast, in Tera-2 RA cells a 6.4 and a 3.0 kb 
transcript are present, for which transcription is driven by the promoter
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upstream of exon 1. Since the 6.4 kb transcript generates the functional, full 
length PDGF a-receptor, this promoter has been used for the current 
activation studies with Pax1. The -994/+118 region of the human PDGFRA 
promoter contains the larger part of the information required for tissue 
specific regulation in transgenic mice, as previously shown by us (15). This 
promoter fragment contains multiple putative Pax1 binding site core 
elements (5’-GTTCC-3’ (6)). Additional mutation studies will have to 
indicate whether PAX1 actually binds to the PDGFRA promoter directly, or 
rather mediates its effect via interaction with other components of the 
transcription machinery.
In summary, the present results emphasize the relevance of Pdgfra 
expression regulation during vertebral column development and support the 
model that impaired expression of this gene may be causally related to spina 
bifida. Evidence from the transfection studies suggests that Pax1 is indeed an 
upstream regulator of PDGFRA and mutations in Pax1 may result in a gain- 
of-function of the protein. The different activities of the wild-type and 
mutant Pax1 proteins correlate with an altered conformation of the 
corresponding protein-DNA complex in the bandshift assays. The present 
data corroborate our earlier hypothesis that mutations in PAX1 can act as risk 
factors in NTD, but also present the PDGFRA gene as the central gene 
involved. Additional studies of this gene have to be performed to investigate 
whether mutations in PDGFRA directly contribute to human NTD, 
particularly to spina bifida.
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Materials and methods
Pax1 constructs
The HCMV wild-type Pax1 expression construct containing the full length 
murine Pax1 cDNA as well as the HCMV full-length Pax1 undulated 
construct (6) were kindly provided by R. Balling (Munich, Germany). In 
order to generate the sb-Pax1 mutant the Gln at position 42 of the paired 
domain was replaced by a His corresponding to the mutation previously 
found in a patient with spina bifida (9). Mutagenesis experiments were 
carried out using the Altered Sites System kit (Promega) according to the 
manufacturer’s protocol using oligonucleotide primer 5'- 
GAGACCCGCAGGTGCCTACTGAT-3'. Presence of the mutation (bold) 
was confirmed by dyedeoxy termination cycle sequencing (ABI) of the 
constructs on an ABI370A automated sequencer.
In vitro transcription/translation
The synthesis of wild-type Pax1, sb-Pax1 and un-Pax1 proteins was 
performed using the TnT-T7 Coupled Promega Rabbit Reticulocyte Lysate 
System (Promega) according to the manufacturer's protocol. For this purpose 
a T7-promoter was introduced by PCR on Pax1 expression constructs, which 
encode Pax1 (wt-Pax1), undulated (un-Pax1) or spina-bifida derived Pax1 
(sb-Pax1), respectively. Forward primer (including T7 promoter and start 
codon) 5'~CGCTAATACGACTCACTATAGGAACAGACCACCATGGA 
GCAGACGTACCGAAGTGAAC~3' and reverse primer 
5'~GGCTGTGGCTCTGTGAGAG~3' (located in 3' UTR, (6)) were used to 
generate the wt-Pax1, un-Pax1 and sb-Pax1 encoding templates. These 
templates were subsequently used for in vitro transcription/translation.
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Generation o f Pax1-specific antibodies
Pax 1-specific polyclonal antibodies were obtained by immunizing two 
rabbits with a Pax1-specific peptide coupled to maleimide-activated keyhole- 
limpet-hemocyanin (Pierce, Illinois, USA) according to the manufacturer’s 
instructions and established protocols (16). The Pax 1-specific peptide 
(NH2)-FKHREGTDRKPPSPG-(COOH) corresponds to amino acid number 
327-341 of the Pax1-protein (6). A total of 1 mg of coupled protein was 
mixed with incomplete Freund’s adjuvans and used for initial immunization. 
Booster injections with 100 ^g of coupled protein were given in 4 weeks 
intervals. Total serum was collected 11 days after the fourth boost, 
designated as 289-IV, and used in these studies.
Western blotting
Protein extracts were separated on a 10% SDS-polyacrylamide gel and 
subsequently transferred to a nitro-cellulose membrane which then was pre­
treated for 20 min with blocking buffer (0.4% gelatine; 3% BSA; 10 mM 
Tris pH 7.5; 350 mM NaCl). The membrane was subsequently incubated 
with the Pax1 antibody (diluted 1:200 in RIA buffer: 10 mM Tris pH 7.5; 
160 mM NaCl; 1% Triton; 0.1% SDS; 0.5% sodium-desoxycholate) for 1 hr 
at room temperature and treated with goat-anti-rabbit alkaline phophatase 
conjugate for 1 hr at room temperature (BioRad; dilution 1:5000 in RIA 
buffer). The membrane was then treated with APB buffer (100 mM Tris pH 
9.5; 100 mM NaCl; 5 mM MgCl2) and subsequently stained using 
bromochloroindolylphosphate and nitrobluetetrazolin as substrates.
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Electrophoretic mobility shift assay (EMSA)
In these assays a 32P-3' end-labelled PRS4 oligonucleotide was used as 
described (6) (5'-TGGGCTCACCGTTCCGCTCTAGATATCTCGA-3'). 
The assays were performed essentially as described previously (17, 18).
Cell culture
Tera-2 EC cells (clone 13) were grown in alpha modification of minimal 
essential medium lacking nucleosides and deoxynucleosides, supplemented 
with 10% (v/v) fetal calf serum and 44 mM NaHCO3 in a 7.5% CO2 
atmosphere at 37° C. Undifferentiated Tera-2 EC cells were seeded at high 
density (5.0x104 cells/cm2). Differentiation of cells was induced by the 
addition of retinoic acid (5 ^M) 12 h after the cells were seeded at low 
density (5.0 x 103 cells/cm2) and maintained in this medium for 7 days prior 
to further use. U-2 OS cells were seeded at high density (5.0x104 cells/cm2) 
and grown in Dulbecco’s MEM/nutrient mix F12 (1:1) with supplements and 
conditions as mentioned above.
Transfection, luciferase, and beta-galactosidase assays 
The -944/+118 human PDGFRA promoter construct (14,15) and expression 
vectors containing no insert, wt-Pax1, sb-Pax1 and un-Pax1 encoding inserts, 
respectively, were transiently transfected into either undifferentiated, or 
retinoic acid differentiated Tera-2 cells or U-2 OS cells using the calcium 
phosphate coprecipitation method (19). Luciferase activity was detected 48h 
post-transfection (Luciferase assay kit, Promega). The luciferase activity was 
corrected for transfection efficiency by measuring the beta-galactosidase 
activity due to a co- transfected CMV-driven lacZ gene construct. 
Transfections were done in duplicate with different batches of DNA.
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Transcription of the PDGFRA gene is regulated 
by a new complex containing 
neural tube defect-associated PRX homeobox 
transcription factors
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Abstract
We have previously shown that specific combinations of PDGFRA promoter 
haplotypes with distinct transcriptional activity predispose to neural tube 
defects (NTDs) in humans. Moreover, we have shown that mutant forms of 
PAX-1, that have been associated with NTDs in both men and mice, induce 
deregulated activation of PDGFRA promoter activity. In the present study 
we have investigated the transcription factors that control the upregulation of 
PDGFRA expression during differentiation of early embryonal human cells 
in culture. In Tera-2 embryonal carcinoma cells PDGFRA expression is 
strongly enhanced upon differentiation induced by retinoic acid and cAMP 
treatment. Here we show that the corresponding increase in promoter activity 
is controlled by an ATTA-sequence containing element located near the 
transcription initiation site, which is bound by a novel transcriptional 
complex that includes PRX and PBX homeobox transcription factors. 
Mutation of the putative binding sites for these transcription factors results in 
strong impairment of PDGFRA promoter activity in differentiated cells. 
Since functional inactivation of Prx genes has been associated with NTDs in 
mice, these data support a model in which improper PDGFRA expression as 
a result of mutations in or altered binding of its upstream regulators may be 
causally related to NTDs.
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Introduction
Neural tube defects (NTDs), including anencephaly and spina bifida, form a 
major group of congenital malformations with an average incidence of 1 per
1,000 pregnancies. NTDs are generally accepted to represent multifactorial 
traits with genetic and environmental factors contributing to their aetiology. 
Several candidate genes for NTDs have emerged from studies on mouse 
models, but only few of them have actually been associated with human 
NTDs. Mice with a targeted null mutation in the gene encoding the platelet- 
derived growth factor a-receptor (Pdgfra) and also so-called Patch mutant 
mice with a natural deletion of the chromosomal region that includes Pdgfra 
both show severe spina bifida combined with embryonic lethality in their 
homozygous form (1, 2). We have recently shown that this gene also plays a 
prominent role in the genesis of NTDs in humans. Based on an analysis of 
naturally occurring single nucleotide polymorphisms in the PDGFRA 
promoter, five different promoter haplotypes could be discriminated which 
strongly differ in their transcriptional activity. Specific combinations of such 
haplotypes correlated directly with a predisposition for NTDs in a group of 
sporadic spina bifida patients (3). Based on these observations we have 
postulated that aberrant transcriptional regulation of PDGFRA may play a 
central role in the genesis of NTDs.
The above hypothesis implies that transcription factors that act as 
upstream regulators of PDGFRA expression may also be associated with 
NTDs. In line with this concept, it has been shown that mice heterozygous 
for the Patch mutation (deletion including the Pdgfra gene) show spina 
bifida only in combination with the so-called undulated mutation in the Pax-
83
Chapter 5
1 homeobox gene (4). In a previous study we have shown that Pax-1 indeed 
acts as an upstream transcriptional regulator of PDGFRA (5). Moreover we 
have shown that Pax-1 carrying the undulated mutation, as well as a mutant 
form of PAX-1 found in a patient with spina bifida (6), show a gain of 
function in their ability to stimulate PDGFRA transcription (5). Also other 
transcription factors that in mouse models have been associated with NTDs, 
including Pax-3 (7), Gli 2,3 (8), HoxD4 (9, 10) and Mfh-1 (11) have been 
directly associated with Pdgfra transcription or at least coexpress with 
Pdgfra during development.
Expression of the PDGF a-receptor and thus responsiveness of cells to 
the various PDGF isoforms (homo- and heterodimeric forms of PDGFA, 
PDGFB, PDGFC and PDGFD) is strictly regulated during embryonic 
development. Although present in all cells of the pre-implantation embryo 
from the two-cell stage onwards (12), Pdgfra expression becomes limited to 
mesoderm and certain neural crest-derived structures after implantation (13­
17). Human embryonal carcinoma (EC) cells, which represent the 
undifferentiated stem cells of non-seminomatous testicular germ cell tumors, 
are widely used as an in vitro model system for studying differentiation- 
dependent regulation of gene expression during early human development 
(18). In previous studies we have shown that the Tera-2 cell line in its 
undifferentiated state (Tera-EC) expresses PDGFRA from an internal 
promoter, giving rise to a set of alternative transcripts that have been used as 
a specific marker for early detection of testicular germ cell tumors (19, 20) . 
Upon in vitro treatment with retinoic acid (RA) differentiated cell 
populations are obtained with neuronal and endodermal characteristics, 
designated Tera-RA, which abundantly express the 6.4 kb PDGFRA 
transcript, that encodes the full length functional PDGF a-receptor. Using 
the cloned 2 kb promoter region of human PDGFRA that drives the
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formation of this 6.4 kb transcript, we have shown in transient transfection 
assays with a luciferase read-out, that PDGFRA transcription is strongly 
upregulated upon treatment of Tera-EC cells with RA, particularly in 
combination with dibutyryl-cAMP (Bt2cAMP), this in spite of the fact that 
the promoter does not contain a consensus RA-responsive element or cAMP­
responsive element.
Based on the hypothesis that aberrant expression of PDGFRA during 
development can be associated with NTDs, we have investigated in the 
present study the transcription factors that are involved in the up-regulation 
of PDGFRA promoter activity during RA-induced differentiation of Tera-EC 
cells. Here we show that an ATTA-sequence containing element (parATTA) 
is essential for PDGFRA transcriptional activity by binding a new complex 
of transcription factors that includes the homeobox proteins PRX-2 and 
PBX-2. Intriguingly, in mouse models Prx genes have been found to be 
associated directly with NTDs. These data underline the central role of the 
PDGFRA expression levels in the genesis of NTDs.
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Results
We have previously shown that the activity of the PDGFRA promoter is 
strongly upregulated upon retinoic acid (RA) treatment of undifferentiated 
Tera-2 human embryonal carcinoma cells. Upregulation was also observed in 
the presence of Bt2 cAMP, such that synergy in promoter activation was 
observed by a combination of RA and this cAMP analogue (23). Since the 
promoter region tested does not contain an obvious sequence with similarity 
to the known RA or cAMP responsive elements, a panel of progressive 5’ 
deletion mutants of the promoter, cloned into a luciferase reporter gene 
vector, was used to map the cis-element(s) involved in the RA- and cAMP- 
induced promoter activity. Upon transient transfection into undifferentiated 
Tera-EC cells, all promoter deletion mutants showed a 9- to 20-fold 
induction of activity, when treated for 48 hours with RA or a combination of 
RA, Bt2 cAMP and theophylline (RACT), as shown in figure 1. Interestingly, 
similar results were obtained when the transfections were performed in RA- 
differentiated Tera-2 (Tera-RA) cells. Since these differentiated cells already 
display a high basal PDGFRA promoter activity (23), RA and RACT seem to 
enhance, rather than induce, promoter activity. From these data we conclude 
that most likely RA and Bt2cAMP mediate their effect through regulating 
elements within the -52/ +118 region of the PDGFRA gene.
To characterize the transcription factors that bind to this specific 
promoter region, electrophoretic mobility shift assays (EMSAs) were 
performed using the -52/ +118 promoter fragment as a probe. At least four 
different complexes were observed upon incubation of this fragment with 
nuclear extracts of Tera-EC cells, as shown in figure 2 (lane 1). Upon 24
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hours treatment of these cells with RA, quantitative changes were observed 
in the three low mobility complexes, while the high mobility complex had 
disappeared in favour of two new complexes with even higher mobility. 
Qualitatively similar differences, although often more pronounced, were 
observed 24 hours after treatment with RACT (23). These data show that RA 
treatment of Tera-2 cells results in a complex but characteristic change in 
nuclear protein binding to the -52/+118 promoter fragment of PDGFRA.
Tcra-2 EC Tera-2 RA
construct RA RACT RA RACT
-52/+U8LUC 9.3 ±  0.1 16.5 ± 0.0 2.5 ±  0.2 10.7 ± 0.2
-175/+ 118LUC 7.9 ±  0.1 22.4 ±  1.0 3.1 ±  0.3 11.8 ±  0.3
-197/+ 118LUC 6.1 ±  0.7 25.8 ± 0.7 2.6 ± 0.0 13.6 ±1.7
-275/+118LUC 9.3 ± 0.4 16.3 ± 0.9 2.2 ± 0.4 18.6 ± 0.6
-441/+ 118LUC 9.2 ±  0.7 21.9 ±  1.8 3.8 ± 0.3 8.8 ±  0.2
-825/+118LUC 6.2 ± 0.0 18.8 ± 2.1 3.2 ± 0.1 11.9 ±  1.0
Figure 1. RA- and cAMP-induced activity of PDGFRA  promoter deletion mutants.
A panel of 5’ promoter-LUC deletion mutants was transfected into undifferentiated 
embryonal carcinoma cells (Tera-2 EC) or RA-differentiated cells (Tera-2 RA). The 
cells were subsequently treated with 5 ^M RA or a combination of 5 ^M RA, 1 mM 
Bt2cAMP and 350 ^M theophylline (RACT) for 48 hrs. After this incubation period, 
luciferase activity in the cells was determined and corrected for transfection 
efficiency (see Materials and Methods). The values represent the fold induction of 
luciferase activity after treatment, relative to the luciferase activity of unstimulated 
cells including the sample standard deviation (duplicate determinations).
87
Chapter 5
The PDGFRA promoter contains various putative binding sites for RA- 
inducible transcription factors as AP2 (23), and one such AP2 site 
(+97GCCGTGGG+104) is located within the -52/+118 region. In addition, an 
ATTA containing sequence (+4ATTGAATCAATTA+16), designated here as 
parATTA, is present with strong homology to a cAMP responsive element 
(TGACGTCA) and to binding sites for the AP1 transcription factor complex 
(TGASTCA; see ref. 24, 25). The involvement of these sequences in the 
binding of nuclear proteins to the -52/+118 region was further investigated 
by oligonucleotide competition studies, as shown by the results in figure 2. 
Competition with the unlabelled parATTA oligonucleotide resulted in a 
complete loss of five of the above six protein-DNA complexes bound to the - 
52/+118 probe. A consensus APl oligonucleotide had no effect on protein 
binding to the —52/+118 fragment, while an AP2 oligonucleotide and an 
oligonucleotide containing a cAMP responsive element (CRE) did also not 
result in binding competition (26). Thus, the parATTA sequence appears to 
be the target element involved in most of the RA-induced changes in protein 
binding to the -52/+118 region.
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Figure 2. Electrophoretic mobility shift analysis of nuclear extracts from untreated 
and RA- treated Tera-2 cells. A [32P]-labelled PDGFRA promoter fragment, 
encompassing nucleotide -52 to + 118 was incubated with nuclear extracts from 
untreated Tera-2 EC cells (CONTROL) and cells treated for 24 hrs with 5 |J,M RA. 
The resulting protein-DNA complexes were analysed by polyacrylamide 
electrophoresis and visualized on X-ray film. Six specific protein-DNA complexes 
were observed. Three of these complexes were induced upon RA treatment (<), 
whereas two protein-DNA complexes decreased in intensity after treament of Tera-2 
EC cells with RA (>). In addition, an approximately 500-fold excess of unlabelled 
competitor DNA (AP1, AP2, CRE and parATTA, as described and indicated) was 
added to the reaction mixtures. Only the parATTA oligonucleotide (ATTA) 
competes with the -52/+ 118 promoter fragment for specific protein binding.
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The ATTA motif is known to be involved in the DNA binding of 
homeobox-containing transcription factors. A search for transcription factor 
binding sites (TFSEARCH analysis) revealed specific binding sites in 
parATTA for members of the PBX and PRX families of homeobox proteins. 
Interestingly, both Prx-1 and Prx-2 have been associated with NTDs in 
mouse studies. In order to identify the factors that bind the parATTA 
sequence in Tera-2 cells, we used specific antibodies directed against PBX 
and PRX proteins in EMSA studies. Figure 3 shows that upon incubation of 
parATTA with nuclear extracts of Tera-EC cells, a reduction in gel mobility 
of the DNA-protein complex was observed in the presence of antibodies 
specific for PBX-2. Moreover, a supershift was observed when the 
experiment was carried out in the presence of antibodies specific for PRX-2, 
while antibodies that recognise both PRX-2 and its transcriptional partner 
PRX-1 (27-29) seem to inhibit DNA-protein complex formation. These data 
indicate that the parATTA sequence is bound by a protein complex which 
contains at least PBX-2 and PRX-2, and possibly also PRX-1. Similar results 
were obtained using nuclear extracts from Tera-RA cells (data not shown).
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Figure 3. Identification of PBX2 
and PRX 1/2 by electrophoretic 
mobility shift analysis. Incubations 
of the [32P]-labelled ATTA 
containing sequence with Tera-EC 
nuclear extracts (ne) and rabbit 
control serum (serum) were 
compared with incubations 
including nuclear extracts and 
serum with specific antibodies 
directed against PBX2 (apbx2) 
and at PRX2 (aprx2) or both 
PRX1+2 (aprx1/2). In lane 4 both 
apbx2 and aprx2 were used in 
combination (apb/rx2). The lower 
arrow indicates the
PBX/PRX/DNA complex; the 
upper arrow indicates the 
supershift caused by aprx2.
In order to analyse specific functions of the different proteins bound to 
parATTA, we introduced inactivating mutations into the parATTA sequence 
specific for binding of either PBX2 or PRX1/2 (based on TFSEARCH 
analysis). Figure 4 shows that the parATTA sequence is strongly reduced in 
its ability to bind Tera-2 nuclear proteins after mutation of either the putative 
binding site for PBX (m-PBX) or that for PRX (m-PRX) transcription 
factors. Introduction of both (7 nucleotides in total) mutations almost fully 
impaired protein binding. This indicates that inhibition of the binding of one 
factor most likely blocks the formation of the entire complex. This is in 
agreement with the finding that PBX transcription factors can only form 
stable complexes with DNA in the presence of other homeobox genes, such 
as in this case PRX1/2 (30).
* 3  S 'S 
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> g g Figure 4. Protein binding abilities of mutated
H o* p p  parATTA DNA sequences. In this EMSA
* Tera-EC nuclear extracts were incubated with
parATTA oligonucleotides with or without 
PBX and/or PRX specific mutations (m-pbx, 
m-prx and DM: Both mutations). The protein 
complexes show a significantly lower affinity 
for the mutated parATTA sequences resulting 
^  in a reduced DNA -protein complex (arrow).
Functional analysis of the wild type and various mutated parATTA 
elements was subsequently studied within the context of the highly active - 
441/+118 promoter-luciferase reporter construct. When transfected into 
Tera-EC cells the PBX/PRX mutations in the parATTA element caused a 
severe reduction in promoter activity compared to the wild-type promoter, as 
shown in figure 5. Deletion of 11 nucleotides of the palindromic sequence 
within the parATTA (A11), while leaving the transcription initiation site 
intact, gave rise to an almost completely inactive promoter with hardly any 
response to RACT. These data are in line with an essential role of the 
parATTA element in normal transcriptional activity of the PDGFRA 
promoter, most likely by forming multiple protein complexes which include 
PBX2 and PRX1/2.
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Figure 5. Effects of mutations introduced in the parATTA element in -441/+118 
promoter luciferase constructs were studied in transient transfection assays. The 
wild type —441/+118 (P1) and constructs containing PBX or PRX specific mutations 
or both (mpbx, mprx, Dm), or carrying an 11 nucleotide deletion (A11), were 
transfected into Tera-2 EC. The cells were subsequently treated for 48 hrs with 
RACT (+) or not (-), after which the luciferase levels within the cells were 
determined and corrected for transfection efficiency. The values represent promoter 
activity by measured luciferase activity relative to ß-galactosidase activity. Error 
bars indicate sample standard deviation of duplicate determinations.
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Discussion
In the present study we have shown that the upregulation of PDGFRA 
expression during differentiation of early embryonic human cells requires a 
promoter element, designated parATTA, which binds a novel complex of 
PRX and PBX proteins. Various studies have shown that improper 
expression of PDGFRA during embryonic development can result in NTDs, 
and therefore both PDGFRA itself and genes encoding upstream regulators 
of its expression may be associated with such malformations. We have 
previously shown that PAX-1, as product of a NTD-associated gene, is an 
upstream regulator of PDGFRA expression, while the current study identifies 
PBX-2, PRX-2 and possibly also PRX-1 as regulators of PDGFRA 
expression that are potentially involved in NTDs. These observations are in 
line with mouse studies, where severe NTDs have been observed in Prx-1 (-/- 
); Prx-2(-/-) mice (29), with similar vertebrae defects as seen in the Pdgfra 
null mutant.
The exact nature of the protein complex that binds the parATTA element 
in Tera-2 cells is unclear, but the observation that five distinct DNA-protein 
complexes have been identified in this study that are competed in 
electrophoretic mobility shift assays by unlabelled parATTA containing 
oligonucleotides, indicates that multiple complexes are formed. This 
suggests that in addition to PBX-2 and PRX1/2 also other proteins may be 
present in the complexes formed. The EMSAs indicate that PBX-2 and PRX- 
1/2 containing complexes can be formed with nuclear extracts from both 
undifferentiated and differentiated Tera-2 cells, indicating that the increase 
in PDGFRA promoter activity upon RA treatment is most likely not due to
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the induction of these homeotic genes. These observations suggest that PBX- 
PRX proteins form the core of a larger novel complex that is required for 
transcriptional activation. The formation of this complex is at most only 
partly regulated by the mere availability of the transcription factors involved, 
but most likely requires an additional activation step. This is confirmed by 
the observed synergy between Bt2AMP and RA, which in comparison with 
RA alone gives rise to only quantitative, and not to qualitative changes in 
transcription factor binding to the -52/+118 region (23). Also the 
observation that RACT still stimulates PDGFRA transcription in Tera-RA 
cells supports this hypothesis.
The present data indicate that the parATTA binding proteins PBX-2 and 
PRX-1/2 are essential for formation of the complex that regulates PDGFRA 
expression during embryonic cell differentiation. Homeobox transcription 
factors are known to control expression of other homeotic genes, but only 
few examples are available in which they control expression of non- 
homeotic genes such as PDGFRA. Amino acid alignment reveals that 
members of the PBX and PRX families are 93-99% conserved between 
mouse and human, while the parATTA element itself is 100% conserved 
between rat, mouse and human. This underlines the importance of this 
mechanism for normal vertebrate development.
Studies on the promoters of the human, mouse and rat PDGF a-receptor 
gene have provided evidence for the involvement of GATA-4 (31), PAX3- 
FKHR (7), Pax-1 (5) and C/EBPs (32) in transcriptional control. Potentially, 
the genes encoding these transcription factors can all be involved in the 
development of NTDs. In mice, Pdgfra itself as well as Pax-1, Pax-3, Prx-1 
and Prx-2, which all encode upstream regulators of Pdgfra expression, have 
been associated directly with NTDs. In humans, specific combinations of 
PDGFRA promoter haplotypes have been associated with predisposition to
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NTDs, while also mutations in PAX-1 and PAX-3 are considered to be risk 
factors for human NTDs. Based on our present results, PBX-2, PRX-2 and 
maybe also PRX-1 should also be considered as candidate genes in the 
genesis of NTDs. Further studies will have to indicate if mutations in these 
genes or different expression levels are indeed observed in patients suffering 
from anencephaly and spina bifida.
Materials and Methods
Reporter constructs
The construction of the truncated PDGFRA promoter-luciferase (LUC) 
reporter gene vectors -2120/ +118 LUC, -441/+118 LUC, -275/+118 LUC, -  
197/+118 LUC, -175/+118 LUC and -52/+118 LUC has been described 
previously (23). Mutant forms of these promoter-luciferase constructs were 
generated using the Quick Change Site-Directed Mutagenesis Kit 
(Stratagene).
Cell culture
The human embryonal carcinoma cell line Tera-2 clone 13 was maintained 
in a-modification of minimal essential medium lacking nucleosides and 
deoxynucleosides, supplemented with 10% ES-approved fetal calf serum 
(Gibco BRL). Undifferentiated cells were seeded one day prior to 
transfection at high density (5.0x104 cells/cm2) in a 0.1% gelatin-coated 
tissue culture dish. Differentiation was induced by the addition of 5 ^M of 
retinoic acid (RA) 12h after the cells were seeded at low density (5.0x103
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cells/cm2), and maintained in this medium for 7 days before further use. 
Transfections were carried out using the calcium-phosphate method (21) 
upon addition of 1 ^g/well promoter-luciferase vector. In addition, 50 
ng/well of the lacZ-expressing vector pCH110 (Pharmacia) was 
cotransfected to correct for differences in transfection efficiency. After the 
appropriate incubation times, cells were lysed in reporter lysis buffer 
(Promega). Luciferase activity in the lysate was determined using the 
luciferase assay kit (Promega), according to the manufacturer’s protocol. ß- 
Galactosidase was assayed as described (22) using Galacton plus (Tropix) as 
the substrate.
Electrophoretic mobility shift assays
Nuclear extracts from Tera-2 cells were prepared as described (33). Extracts 
(10-15 ^g) were incubated with 3x104 cpm [32P]-labelled DNA, 2 |ig dI-dC, 
and if necessary unlabelled competitor DNA, in a reaction buffer (20 mM 
Hepes pH 7.9, 50 mM NaCl, 1mM EDTA, 0.15 mM EGTA, 1 mM DTT,
0.15 mM PMSF, 4% (w/v) Ficoll and 50 mM KCl) for 5 min at room 
temperature. The resulting protein-DNA complexes were separated on a 4% 
polyacrylamide gel using 0.5xTBE as running buffer (21) and visualized on 
X-ray film (Kodak X-Omat, Fuji RX).
Synthetic oligonucleotides
The following synthetic oligonucleotides were obtained in single-stranded
form in both the sense and anti-sense direction:
parATTA (5’-CTATAACATTGAATCAATTACAA-3’),
m-PBX (5’-CTATAACAGGGAAGCAATTACAA-3’),
m-PRX (5’-CTATAACATTGAATCTAGAGCAA-3’),
DM (5’- CTATAACAGGGAAGCTAGAGCAA-3’),
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consensus CRE (5’-AGAGATTGCCTGACGTCAGAGAGAAG-3’ ), 
consensus AP1 (5’-CGGATGACTCAGCCGGAA-3’) and 
consensus AP2 (5’-GATCGAACTGACCGCCCGCGGCCGT-3’).
Equal amounts of the sense and anti-sense oligonucleotide were mixed in 
distilled water, heated to boiling temperature and slowly cooled to room 
temperature. If necessary, the resulting double stranded product was 
subsequently purified by non-denaturating polyacrylamide gel 
electrophoresis (21).
Antibodies
Anti-PBX polyclonal antibodies were directed against the C-terminus of the 
human protein, recombinantly prepared as a GST fusion protein (a generous 
gift from Dr. C. Murre, UCSD). Polyclonal antibodies specific for PRX-2 
(aPrx2) were directed against a synthetic peptide derived from mouse Prx2 
(IKSYGQEAAIEQPVAPRPTT), while polyclonal antibodies recognizing 
both PRX-1 and PRX-2 (aPrx1+2) were generated against the E.coli 
recombinant protein
AGRRAAGPVSGPAEARVGAAREPSGGSSGTEAAPQDGDCPSPGRGT 
KRKKKQRRNRTTFNSSQLQALERVFERTHYPDAFVREELARRVNLSE 
ARVQVWFQNRRAKFRRNERAMLATRSASLLKSYGQEAAIEQPVAPR 
PTTMSPDYLSWPASSPYSSVPPYSPGGSSPATPGVNMANSIASLRLKA 
KEFSLHHSQVPTVN. Both antibodies were a generous gift from Dr. F. 
Meijlink, Hubrecht Laboratory, Utrecht.
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General discussion
General discussion
PDGFRA and its role in neural tube defects
Mouse studies have shown a direct correlation between expression levels of 
Pdgfra and the occurrence of neural tube defects. These results are mainly 
based on mutant mice in which either the gene itself or genes for upstream 
regulators of Pdgfra are affected. The present studies were undertaken to 
investigate if also in humans the PDGFRA gene is involved in NTDs. We 
have therefore cloned the PDGFRA promoter, and shown that a number of 
genes known to be involved in NTDs in mice encode proteins that act as 
transcription factors for the human promoter. Moreover, we have shown that 
different haplotypes of the PDGFRA promoter exist, and that combinations 
of different haplotypes can be correlated with the incidence of spina bifida in 
a group of Dutch patients.
Deregulation o f transcription
Studies on the human, mouse and rat platelet-derived growth factor a- 
receptor promoters have provided evidence for the involvement of GATA-4 
(1), PAX3(-FKHR) (2), Paxl (chapter 4), PBX2 (chapter 5), PRX1/2 
(chapter 5) and MFH1 (ref. 3, and data not shown) in transcriptional 
activation of this gene. All of these transcription factors have previously 
been associated with NTDs. Other transcription factors that are known to 
activate PDGFRA expression, including Glil (4), HoxD4 (ref. 5, and data 
not shown), c-Jun (ref. 6, and G.B. Afink, thesis University of Nijmegen, 
1996) and C/EBPs (7), also play a prominent role in normal (neural) 
embryonic development, but so far they have not been associated with
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NTDs. Also molecules that can act downstream of the PDGFRA such as c- 
Abl, c-Cbl, inositol derivatives and collagen type II have been associated 
with multiple developmental defects including NTDs (8-10). These data, 
combined with the Patch and Pdgfra null mouse models for NTDs, suggest a 
critical role for platelet-derived growth factor a-receptor in NTD genesis, at 
least in mice. In humans, no genetic defects could be detected in the protein­
encoding part of PDGFRA in NTD patients (F. Hol, unpublished 
observation). In mouse models the complete absence of Pdgfra function 
appears to be lethal, and since spina bifida patients are viable, we 
hypothesise that in these patients a subtle disturbance of axial development 
by a deregulated action of one of the multiple factors involved in PDGFRA 
transcription contributes to NTDs. The non-syndromic majority of NTDs in 
human patients implicates a localised defect that could be caused by a 
mutated site-specific transcription factor, or by mutations in transcription- 
regulated sequences of the PDGFRA gene, required for site-specific 
expression. Dose effects as a result of deregulated expression can explain the 
variable penetrance of the NTD phenotype observed in both humans and 
mice, since they can be compensated by a variety of genetic and 
environmental factors.
The data presented in this thesis confirm this hypothesis by showing that 
NTDs can be accompanied by deregulated transcription which occurs as a 
consequence of mutated PDGFRA transcription regulating sequences or an 
altered function of upstream regulators. In addition combinations of specific 
PDGFRA promoter haplotypes can predispose to defects in embryonic 
development, including NTDs. These data confirm our hypothesis that 
deregulation of PDGFRA transcription is an important event in NTDs 
genesis.
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Paired-related genes
Several gene products with an important function in neural tube and/or 
vertebral column development act upstream of PDGFRA. A group 
specifically associated with PDGFRA transcription is formed by the class of 
so-called paired (prd)-related genes. This class includes genes belonging to 
the Pax gene family. The extensive analysis of Pax genes has been an 
important contribution towards our understanding of the signalling network 
that controls somite compartmentalization and differentiation.
Pax-1 and Pax-9 were found to play an important role in the development 
of the sclerotome (11). In the mouse mutants Undulated and Undulated- 
short-tail (Un and Uns) Pax-1 is mutated or the complete Pax-1 locus is 
deleted, respectively. Pax-l-deficient “Uns” mice lack the ventral vertebral 
bodies and intervertebral discs and show an enlarged notochord with an 
increased proliferation rate (12). Pax-1/Pax-9 double mutants possess neural 
arches but completely lack vertebral bodies, intervertebral discs and 
proximal ribs (13). Mice homozygous for the gain of function mutation Un 
show a three days delay in axial skeleton development which results in less 
severe skeletal defects (14, 15). In contrast, when homozygous Un is 
combined with heterozygous Patch (Pdgfra deletion), development of the 
dorsal vertebrae is affected, which results in spina bifida occulta (16). 
Actually these mice were the first examples to show multiple gene 
involvement in NTD genesis.
Another Pax family member, Pax-3, is expressed in the dorsal neural 
tube. In Splotch mice, in which the homeobox domain encoding part of the 
Pax-3 gene is mutated, the development of the dorsal part of the neural tube 
is affected, also resulting in spina bifida (2, 17). Pdgfa and its receptor 
Pdgfra have been suggested to act downstream of Pax-3 (18), while Pax3- 
FKHR alters Pdgfra transcription (2). In humans PAX3 mutations have been
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found in patients with Waardenburg syndrome accompanied by spina bifida 
(19, 20).
Other transcription factors that have been included in the axial network 
are Zic1, Gli3 and Mfh1. Sclerotome cells expressing both Zic1, Gli3 and 
Pax1 may contribute to the formation of vertebral arches. Interestingly, the 
mitosis of sclerotome cells is most active in Zic1/Pax1 co-expressing region 
(3). The abnormalities in the vertebral arches of Zic1/Pax1 and Zic1/Gli3 
double KO mice are significantly more severe than in Zic1 single mutants. 
This suggests the Zic1 protein to be involved in the proliferation of the 
sclerotome cells in this region in collaboration with Pax1 and Gli3. 
Alternatively, Zic1, Gli3 and Pax1 proteins might synergistically affect the 
responsiveness of sclerotome cells to vertebral arch-inductive signals, such 
as BMP-4 (21, 22) and PDGF (16, 23). In Mfh1/Pax1 double mutants, 
dorsomedial structures of the vertebrae are missing, resulting in extreme 
spina bifida accompanied by subcutaneous myelomeningocoele, while in 
addition vertebral bodies and intervertebral discs are missing. These 
morphological defects in Mfh1/Pax1 double mutants also strongly correlate 
with a reduction in the mitotic rate of sclerotome cells. Here the Mfh1 and 
the Pax1 gene products cooperate to mediate the anti-apoptotic Sonic 
hedgehog (SHH) signal in sclerotome cells (3, 24). Interestingly, both Pax1 
and Mfh1 have been shown to regulate the activity of human PDGFRA 
promoter constructs (see chapter 4 and Joosten et al., unpublished 
observation).
Prx1 and Prx2 (previously known as MHox and S8, respectively) belong 
to a subclass of paired-related, non-Pax homeobox genes that are expressed 
in specific patterns in the embryonic mesenchyme. Very similar to the axial 
defects in Pdgfra null mutants, the dorsal processes of the thoracic and 
lumbar vertebrae are absent in Prx1 -/- mutants, and the neural arches spread
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out laterally, resulting in spina bifida (25, 26). Prx1 -/-, Prx2 -/- double 
mutants show in addition absence of the dorsal processes of the cervical 
vertebrae including the atlas and axis (26). Like many Hox genes, the Prx 
genes contribute to morphogenesis of the skeleton as an implication of their 
general role in rostro-caudal patterning. Prx1 and Prx2 may influence 
sclerotome condensation in response to local positional cues, while in 
addition they also influence local growth rates in specific bones during foetal 
stages by altering for instance Pdgfra expression (chapter 5), thereby 
shaping the bone.
chondroblasts of
vertebral primordium
Figure 1. Sequential stages of axial sclerotome development. Pdgfra function is 
important during the morphogenetic events of the paraxial mesoderm which result in 
axial skeleton formation. The receptor is expressed in all stages from presomitic 
mesoderm to the vertebral primordium and in glia precursor cells within the neural 
tube. The other factors depicted have been shown in mouse models to be essential 
for normal development, often linked to Pdgfra expression or function.
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Growth balance
A fine balance between proliferation, apoptosis and differentiation of 
sclerotome cells is necessary for proper development of the dorsal 
sclerotome. Pdgfra and Pax-l contribute to this in concert with other factors 
such as Pax-9, Zic-1, Gli3, Mfh1 and Prx1/2 (Fig. 1). During embryo-genesis 
the development of neural and skeletal structures depends on cell selection 
on the basis of localisation clues provided by gradients in morphogenetic 
factors, cell/cell contacts and extracellular matrices. Cells that do not receive 
sufficient amounts of the appropriate signals to proceed in differentiation are 
largely prone to apoptosis. Migrating cells are probably particularly 
susceptible to apoptosis since they leave their original environment and have 
to survive until they reach a suitable new environment for further 
development. It is an attractive hypothesis that sufficient Pdgfra expression 
levels are essential for survival of these cells. It has been proposed that also 
folic acid, which is known to be required for proper closure of the neural 
tube in humans, might also have an anti-apoptotic influence in this process 
(27). This could link the protective effect of folic acid supplementation to 
several genes with involvement apoptosis-related NTDs, including PAX1 and 
PDGFRA.
Normal embryogenesis can be severely impaired when the development 
of different tissues proceeds out of balance. When, due to for instance 
deregulated apoptosis, neural tissue growth is impaired, the development of 
the neural arches, which is dependent on neural signalling, will also be 
affected (28). When on the other hand mesodermal tissue growth is impaired, 
it may prevent the neural tube to close, as is shown in the curly tail embryos 
(29). In fact many mouse NTD models show site-specific enhanced 
apoptosis, which suggests that in many cases NTDs arise not because of the 
inability of the embryo to form specific structures, but rather because of the
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inability to form the structures within a certain time window due to enhanced 
apoptosis. The apoptosis-related mechanism seems to fit well with the multi­
factorial model proposed for human NTDs .
Aberrant PDGFRA transcription as a central event in NTD genesis 
In our hypothesis, deregulation of PDGFRA transcription is a central event 
in NTD genesis, particulary in spina bifida genesis. Severe changes in 
expression have been shown to be early embryonic lethal in mice, suggesting 
that in viable human patients subtle alterations will be involved. The data 
presented in this thesis confirm this hypothesis, but only in two patients 
molecular defects have been found that might contribute to their NTDs by 
deregulating PDGFRA transcription (single mutations in PAX1 and the 
PDGFRA promoter). Several hypotheses can be proposed to explain how 
haplotype combinations give rise to perturbed PDGFRA transcription and 
thus predispose to NTDs. The involvement of transvection as an additional 
mechanism in regulating PDGFRA transcription is one attractive hypothesis.
Transvection, also referred to as transinduction or as interchromosome 
association, can be considered as an additional layer to regulate transcription. 
It requires physical contact between the two alleles of certain genes which 
alters transcription of each individual allele. This physical interaction 
depends on core promoter elements and genomic position (30, 31). Specific 
haplotype combinations, as found in NTD patients, might give rise to 
perturbed transcription, both contributing to subtle changes in the 
developmental balance that are involved in NTD genesis.
As described previously, yeast artificial chromosome (YAC) transgene 
expression after pronuclear injection of a 380 kb YAC containing the human 
PDGFRA gene was found to rescue the NTDs phenotype targeted Pdgfra 
null mutant mice (37). Interestingly it has also been found that the YAC
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transgene does not rescue homozygous Patch mutant mice totally lacking 
both Pdgfra alleles. This observation suggests that the inserted YACs are 
only able to bypass the defects that are introduced in the targeted knock out 
mice which still have intact transcription regulating DNA sequences of the 
gene at the original locus. Transvection, described predominantly in 
Drosophila but also in yeast and mammalian cells, might be responsible for 
this observation (30-34).
In Drosophila, the physical interaction between different DNA strands 
can be mediated by factors encoded by the essential Trithorax-like genes, 
such as GAGA and Zeste (34, 35), while a homologue of the latter has been 
shown to be involved in neural patterning in Xenopus embryos (36). 
Physical interaction could be initiated when transcription regulating 
sequences are targeted to the same transcriptionally active nuclear domain. 
Subsequently, a cross-interaction of transcription regulating complexes 
might take place. Communication between alleles by direct physical 
interaction provides the differentiating cell with additional tools for fine 
regulation, and could provide explanations for phenomena such as haplo- 
insufficiency, positional effect variegation, allelic exclusion and even X- 
chromosome inactivation. Transvection between PDGFRA alleles could thus 
provide an explanation for several puzzling observations such as; no YAC 
rescue of homozygous Patch mice (37), NTD predisposing combinations of 
PDGFRA promoter haplotypes with distinct activities (38) and the spina 
bifida phenotype of the Patch/Undulated mice (16). It might also explain the 
aberrant c-Kit expression that causes the fur depigmentation (“Patch”) by 
which the Patch heterozygote mice are recognised. The lack of one Pdgfra 
allele possibly perturbs the transvection and transcription in this region 
including the c-Kit gene. These observations suggest that factors which play
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a role in higher levels of PDGFRA transcription regulation, e.g. transvection, 
can also be involved in NTD genesis.
To confirm the present hypothesis about the involvement of transvection 
and apoptosis in NTDs, subsequent research will have to be carried out by 
further analysing PDGFRA transcription regulation, including identification 
of haplotype-specific transcription factors, studies on the nuclear localisation 
of PDGFRA alleles using immuno-FISH techniques, and analysis of mice 
with perturbed Pdgfra expression and/or ability to undergo apoptosis.
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Summary
Neural tube defects (NTDs) including anencephaly and spina bifida are 
among the most common human birth defects, and involve defective 
formation of the brain and/or spinal cord. Epidemiological data show that 
most NTDs occur as a consequence of a complex interaction between 
environmental and a variety of predisposing genetic factors, which is 
indicative for a multifactorial process. Several studies on mouse models with 
NTDs have provided evidence for the involvement of specific genes which 
function during embryonic neural tube development. One of these genes, 
Pdgfra, which encodes the platelet-derived growth factor a-receptor, has 
been the subject of the present studies. So far it has turned out to be very 
difficult, however, to correlate factors associated with NTDs in mice with 
those involved in human diseases (chapter 1).
The present studies were undertaken to investigate whether also in 
humans the PDGFRA gene is directly involved in NTDs. Since the Patch 
and Pdgfra null mouse models for NTDs indicated that Pdgfra has an 
essential role in NTD genesis, but no genetic defects could be detected in the 
protein encoding part of the PDGFRA gene in human NTDs patients, we 
hypothesised that a deregulation of PDGFRA transcription may cause NTDs. 
Accordingly the main objective of the present study was the identification of 
(candidate) genes and mechanisms involved in NTDs genesis in humans and, 
with these, to test the hypothesis of a deregulation of PDGFRA expression. 
We have therefore cloned the PDGFRA promoter (chapter 2) and shown that 
genes known to be involved in NTDs in mice encode proteins that act as 
transcription factors for the human promoter.
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We identified five different haplotypes in the human PDGFRA promoter 
of which the two most abundant ones, designated H1 and H2a, differ in at 
least six polymorphic sites. In a transient transfection assay in human bone 
cells, the five haplotypes differ strongly in their ability to enhance reporter 
gene activity. We found that specific combinations of these naturally 
occurring PDGFRA promoter haplotypes correlate with high NTD incidence 
in humans (chapter 3).
The double mutant (Un/Un, Ph/+) mice were the first examples to show 
multiple gene involvement (Paxl and Pdgfra) in NTD genesis, while also a 
PAX1 mutation was discovered in one spina bifida patient. This PAX1 
mutation is shown to cause aberrant PDGFRA transcription (chapter 4). In 
addition we have shown that two other members of the same class of paired- 
related genes involved in embryonic axial development, Prx1 and Prx2, bind 
an element essential for normal PDGFRA promoter activity in Tera-2 cells. 
Lack of these factors causes an axial phenotype in knock-out mice very 
similar to the Pdgfra null mutants (chapter 5).
The data presented in this thesis confirm our hypothesis by showing that 
in at least some NTDs patients deregulated Pdgfra transcription occurs, due 
to altered function of upstream regulators, such as for instance PAX1. Higher 
susceptibility to deregulation might be caused by specific PDGFRA 
promoter haplotype combinations. A mechanism called transvection, 
described predominantly in Drosophila but also in yeast, plants and 
mammalian cells could provide an explanation for the intriguing 
observations such as the NTD predisposing combinations of PDGFRA 
promoter haplotypes, but also the lack of rescue of homozygous Patch mice 
with PDGFRA containing YACs and the spina bifida phenotype of the 
Patch/Undulated mice (chapter 6).
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Samenvatting
Neurale-buisdefecten (NTDs), waaronder anencephalie en spina bifida, 
behoren tot de meest voorkomende aangeboren afwijkingen bij de mens, en 
zijn een consequentie van afwijkingen in de ontwikkeling van de hersenen 
en/of ruggenmerg. Epidemiologische gegevens laten zien dat de meeste 
NTDs veroorzaakt worden door een complexe interactie tussen 
omgevingsfactoren en een aantal genetische risicofactoren, hetgeen aangeeft 
dat het hier een multifactoriële aandoening betreft. Verschillende studies met 
muismodellen voor NTDs hebben aanwijzingen opgeleverd voor de 
betrokkenheid van specifieke genen met een functie gedurende de neurale 
ontwikkeling van embryo’s. Een van deze genen, genaamd Pdgfra, die 
codeert voor de platelet-derived growth factor a-receptor, is het onderwerp 
van de huidige studies. Het is tot nu toe erg moeilijk gebleken om factoren 
die geassocieerd zijn met NTDs in de muis te correleren met factoren die 
betrokken zijn bij dergelijke ziekten in de mens (hoodstuk 1).
De huidige studies zijn uitgevoerd om te onderzoeken of ook in de mens 
het PDGFRA gen betrokken is bij het ontstaan van NTDs. Omdat de Patch 
en Pdgfra null muismodellen voor NTDs aangetoond hebben dat PDGFRA 
een essentiële rol speelt bij het ontstaan NTDs, maar er echter geen 
genetische afwijkingen in het eiwit coderende deel van het PDGFRA gen 
gevonden zijn bij patiënten, hebben wij de hypothese gesteld dat een 
deregulatie van PDGFRA transcriptie belangrijk is voor het ontstaan van 
NTDs. Om deze hypothese te toetsen hebben wij ons in deze studie tot doel 
gesteld kandidaat-genen te identificeren waarvan de producten betrokken 
zijn bij transcriptionele regulatie van PDGFRA en te onderzoeken via welke 
mechanismen deze genen betrokken zijn bij het ontstaan van NTDs. Wij 
hebben daartoe de PDGFRA promoter gecloneerd (hoofdstuk 2) en laten zien
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dat genen die in de muis betrokken bij het ontstaan van NTDs, in de mens 
coderen voor eiwitten die PDGFRA transcriptie kunnen (de)reguleren.
Wij hebben 5 verschillende haplotypen van de PDGFRA promoter 
geïdentificeerd, waarvan de meest voorkomenden, H1 en H 2a genoemd, 
verschillen op tenminste 6 polymorfe posities. In een transiënte transfectie in 
bot-tumorcellen vertoonden deze verschillende haplotypen sterk 
verschillende activiteiten bij de aansturing van een reportergen. Wij hebben 
gevonden dat specifieke combinaties van deze algemeen voorkomende 
PDGFRA promoter-haplotypen correleren met een hoge incidentie van 
NTDs in de mens (hoofdstuk 3).
De dubbel mutante (Un/ Un,Ph/+) muizen waren het eerste voorbeeld van 
een muismodel waarbij een betrokkenheid van meerdere genen bij het 
ontstaan van NTDs werd aangetoond (Pax1 en Pdgfra). Daarnaast hebben 
wij in een spina bifida patiënt een specifieke mutatie in het PAXl gen 
gevonden. We konden aantonen dat deze PAX1 mutatie aanleiding geeft tot 
een gedereguleerde PDGFRA transcriptie (hoofdstuk 4). Daarnaast hebben 
wij laten zien dat twee andere leden van dezelfde klasse van paired-related 
genen, PRX1 en PRX2, die betrokken zijn bij de axiale embryonale 
ontwikkeling, coderen voor eiwitten die een element binden dat essentieel is 
voor PDGFRA transcriptie in humane Tera-2 embryonale carcinoma cellen. 
Knock-out muizen zonder deze transcriptie-factoren hebben een phenotype 
dat sterke overeenkomsten vertoont met muizen zonder Pdgfra functie 
(hoofdstuk 5).
De gegevens in dit proefschrift bevestigen de gestelde hypothese door te 
laten zien dat specifieke combinaties van PDGFRA promoter-haplotypen 
gecorreleerd kunnen worden met het risico op NTDs. Daarnaast zijn in een 
beperkt aantal NTDs patiënten mutaties in PDGFRA en PAX1 gevonden die 
aanleiding geven tot deregulatie van PDGFRA transcriptie. Deregulatie van
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PDGFRA transcriptie bij combinaties van verschillende promoter- 
haplotypen zou veroorzaakt kunnen worden door een verschijnsel dat bekend 
staat onder de naam transvectie. Dit fenomeen, waarbij promoters van 
verschillende allelen elkaars activiteit kunnen beïnvloeden, is voornamelijk 
beschreven in Drosophila, maar is ook aangetoond in gist, planten en 
zoogdiercellen. Transvectie kan mogelijk een aantal opmerkelijke 
observaties verklaren, zoals de verhoogde gevoeligheid in de humane 
populatie voor NTDs door specifieke PDGFRA-promoter haplotype- 
combinaties, maar ook het feit dat PDGFRA bevattende YAC-transgenen in 
staat zijn het spina bifida phenotype tegen te gaan van Pdgfra -/- muizen, 
maar niet van (Ph/Ph) en (Un/Un,Ph/+) muizen (hoofdstuk 6).
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